[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 194
1. Roeder F, Friedrich J, Timke C, Kappes J, Huber P, Krempien R, Debus J, Bischof M: Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol; 2010 Mar;186(3):149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer.
  • PURPOSE: To analyze the association of patient- and treatment-related factors with the onset of radiation pneumonitis in a homogeneously treated cohort of patients suffering from small cell lung cancer (SCLC).
  • Patient- (age, gender, smoking history, performance status, tumor localization, benign lung disease) and treatment-related parameters (V(10)-V(40), mean lung dose [MLD]) were analyzed using χ(2)-tests for categorical parameters and logistic regression for continuous variables.
  • Considering treatment-related parameters, a significant correlation of V(30) in regard to total lung and V(40) in regard to ipsilateral, contralateral and total lung to the risk of pneumonitis was found.
  • So, the estimated risk of a clinically relevant pneumonitis increased from 10% given a V(30) of 13% to 30% given a V(30) of 35%.
  • In contrast, no significant correlation was found for V(10) and V(20) and only a trend for MLD.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / radiotherapy. Radiation Pneumonitis / epidemiology. Radiotherapy, Conformal / statistics & numerical data. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Feb;184(2):61-6 [18259696.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:3-4 [19685024.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):231-4 [19370425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):329-39 [12243805.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):175-81 [15110451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1208-9; author reply 1209 [12829167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):455-60 [7673033.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1065-70 [8648358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407 [16997503.001]
  • [Cites] Strahlenther Onkol. 2007 Apr;183(4):215-7 [17406804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9 [10487552.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:21-2 [19685030.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):650-9 [11597805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):5-24 [15963660.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183(12):679-84 [18040612.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):112-24 [16618575.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):545-51 [17896085.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):548-56 [14509954.001]
  • [Cites] Strahlenther Onkol. 2009 Jan;185(1):27-33 [19224144.001]
  • [Cites] Strahlenther Onkol. 2008 Jun;184(6):296-301 [18535804.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3201-6 [12874270.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1075-86 [16647222.001]
  • [Cites] Strahlenther Onkol. 2008 Apr;184(4):193-7 [18398583.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):127-38 [15110445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78 [9806503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):106-13 [12694828.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):605-9 [19016020.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):693-7 [8664191.001]
  • [Cites] Strahlenther Onkol. 2008 Jun;184(6):289-95 [18535803.001]
  • (PMID = 20165822.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mourmouras V, Fumagalli S, Biagioli M, Prudovsky I, Miracco C, Santucci M, Marchionni N, Tarantini F: S100A13 is a new angiogenic marker in human melanoma. Mod Pathol; 2010 Jun;23(6):804-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiogenesis is critical in melanoma progression and metastasis and relies on the synthesis and release of proangiogenic molecules such as vascular endothelial growth factor (VEGF)-A and fibroblast growth factors (FGFs).
  • S100A13 is a small calcium-binding protein that facilitates the release of FGF-1, the prototype of the FGF family.
  • S100A13 is upregulated in astrocytic gliomas, in which it correlates with VEGF-A expression, microvessel density and tumor grading, and promotes a more aggressive, invasive phenotype in lung cancer-derived cell lines.
  • We found that S100A13 was expressed in melanocytic lesions; compared with benign nevi, S100A13 protein expression was significantly upregulated in melanomas (P=0.024), in which it correlated positively with the intensity of VEGF-A staining (P=0.041) and microvessel density (P=0.007).
  • In conclusion, S100A13 is expressed in melanocytic lesions when the angiogenic switch occurs and it may cooperate with VEGF-A in supporting the formation of new blood vessels, favoring the shift from radial to vertical tumor growth.
  • [MeSH-major] Biomarkers, Tumor / analysis. Capillaries / chemistry. Melanoma / blood supply. Melanoma / chemistry. Neovascularization, Pathologic / metabolism. S100 Proteins / analysis. Skin Neoplasms / blood supply. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Antigens, CD / analysis. Female. Fibroblast Growth Factor 1 / analysis. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. Receptors, Cell Surface / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94 [10838264.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6199-206 [19917835.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22544-52 [11410600.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):223-35 [11438469.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1826-31 [11919240.001]
  • [Cites] FASEB J. 2003 Jun;17(9):984-92 [12773481.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):990-7 [15133476.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Reprod Domest Anim. 2004 Oct;39(5):321-7 [15367264.001]
  • [Cites] Semin Oncol. 1975 Jun;2(2):119-47 [1234372.001]
  • [Cites] Science. 1984 Aug 31;225(4665):932-5 [6382607.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):99-104 [7686347.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6061-6 [8261423.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):329-36 [8311116.001]
  • [Cites] J Biol Chem. 1995 Dec 8;270(49):29039-42 [7493920.001]
  • [Cites] J Invest Dermatol. 1996 Feb;106(2):207-8 [8601716.001]
  • [Cites] Melanoma Res. 1996 Apr;6(2):133-7 [8791271.001]
  • [Cites] Melanoma Res. 1996 Jun;6(3):223-30 [8819125.001]
  • [Cites] J Cutan Pathol. 1997 Apr;24(4):212-8 [9138111.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):599-623 [9210357.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):464-9 [9291441.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):70-4 [10030417.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):770-4 [10463478.001]
  • [Cites] Reprod Biol. 2005 Mar;5(1):51-67 [15821778.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1955-8 [15900299.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):4993-7 [15958538.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):87-101 [16165218.001]
  • [Cites] Biochem J. 2006 Jun 1;396(2):201-14 [16683912.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):251-9 [16773219.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6):555-65 [18083379.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):151-9 [18061437.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):357-64 [17566693.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1327-43 [17786931.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Neoplasma. 2008;55(4):273-9 [18505336.001]
  • [Cites] Cancer Lett. 2008 Aug 18;267(1):67-74 [18400376.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):21-30 [18660796.001]
  • [Cites] Ann Oncol. 2009 Aug;20 Suppl 6:vi8-13 [19617299.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1717-26 [11245488.001]
  • (PMID = 20208480.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL035627; United States / NHLBI NIH HHS / HL / R01 HL035627; United States / NHLBI NIH HHS / HL / R01 HL035627-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / S100 Proteins; 0 / S100A13 protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 104781-85-3 / Fibroblast Growth Factor 1
  • [Other-IDs] NLM/ NIHMS204422; NLM/ PMC2882157
  •  go-up   go-down


3. Wee A: Fine needle aspiration biopsy of the liver: Algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma. Cytojournal; 2005 Jun 8;2:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of the liver: Algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma.
  • Guided FNAB is still useful to procure a tissue diagnosis if clinical, biochemical and radiologic findings are inconclusive.
  • Major diagnostic issues include: (i) Distinction of benign hepatocellular nodular lesions from reactive hepatocytes, (ii) Distinction of well-differentiated hepatocellular carcinoma (WD-HCC) from benign hepatocellular nodular lesions, (iii) Distinction of poorly differentiated HCC from cholangiocarcinoma and metastatic carcinomas, (iv) Determination of histogenesis of malignant tumor, and (v) Determination of primary site of origin of malignant tumor.
  • The inherent difficulty of distinguishing small/early HCC from benign hepatocellular nodular lesions has resulted in indeterminate reports.
  • Changing concepts in the understanding of the biological behavior and morphologic evolution of HCC and its precursors; and the current lack of agreement on the morphologic criteria for distinguishing high-grade dysplastic lesions (with small cell change) from WD-HCC, have profound impact on nomenclature, cytohistologic interpretation and management.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):280-8 [1847609.001]
  • [Cites] Radiology. 1991 Jan;178(1):253-8 [1984314.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):1009-13 [2165350.001]
  • [Cites] J Hepatol. 1990 Nov;11(3):344-8 [2290025.001]
  • [Cites] Diagn Cytopathol. 1986 Dec;2(4):290-4 [2431848.001]
  • [Cites] Histopathology. 1989 May;14(5):503-13 [2472345.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):347-54 [7514830.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):596-8 [7539204.001]
  • [Cites] Liver. 1995 Feb;15(1):30-4 [7539880.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):381-8 [8391735.001]
  • [Cites] Acta Cytol. 1993 May-Jun;37(3):300-8 [8498132.001]
  • [Cites] Semin Liver Dis. 1995 Nov;15(4):360-71 [8578320.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):257-62 [8629408.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):51-7 [8630939.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):836-7 [8633567.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):937-47 [8842170.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1167-75 [8863666.001]
  • [Cites] Mod Pathol. 1996 Sep;9(9):901-9 [8878022.001]
  • [Cites] J Hepatol. 1996 Sep;25(3):334-8 [8895013.001]
  • [Cites] Dig Dis Sci. 1996 Dec;41(12):2326-31 [9011437.001]
  • [Cites] Acta Cytol. 1997 Mar-Apr;41(2):583-6 [9100803.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1617-23 [9136841.001]
  • [Cites] Diagn Cytopathol. 1997 May;16(5):383-91 [9143838.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):686-92 [9237179.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1147-55 [9250313.001]
  • [Cites] Histopathology. 1997 Jul;31(1):47-54 [9253624.001]
  • [Cites] Diagn Cytopathol. 1997 Oct;17(4):306-10 [9316789.001]
  • [Cites] Hepatology. 1998 Jan;27(1):273-8 [9425947.001]
  • [Cites] Diagn Cytopathol. 1995 Jun;12(4):364-70; discussion 370-1 [7544724.001]
  • [Cites] Hepatology. 1995 Sep;22(3):983-93 [7657307.001]
  • [Cites] Am J Clin Pathol. 1993 May;99(5):551-7 [7684185.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):453-62 [7762332.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):64-76 [7770675.001]
  • [Cites] Diagn Cytopathol. 1994 Dec;11(4):385-7; discussion 387-9 [7895578.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):232-40; discussion 241 [8050331.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1113-23 [8214256.001]
  • [Cites] Acta Cytol. 1993 May-Jun;37(3):309-16 [8388606.001]
  • [Cites] Mod Pathol. 1997 Dec;10(12):1258-64 [9436973.001]
  • [Cites] Oncol Rep. 1998 Mar-Apr;5(2):355-8 [9468556.001]
  • [Cites] Liver. 1998 Feb;18(1):14-9 [9548262.001]
  • [Cites] Diagn Cytopathol. 1998 Jul 1;19(1):29-32 [9664180.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1216-22 [9797377.001]
  • [Cites] Histopathology. 1998 Oct;33(4):318-24 [9822920.001]
  • [Cites] Semin Diagn Pathol. 1998 Nov;15(4):285-99 [9845429.001]
  • [Cites] Liver. 1999 Feb;19(1):12-8 [9928760.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4 Suppl):1325-8 [9990267.001]
  • [Cites] Acta Cytol. 1999 Mar-Apr;43(2):131-8 [10097699.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):310-7 [10365850.001]
  • [Cites] Acta Cytol. 1999 Jul-Aug;43(4):610-6 [10432883.001]
  • [Cites] Diagn Cytopathol. 1999 Sep;21(3):180-7 [10450103.001]
  • [Cites] Gut. 1999 Oct;45(4):626-7 [10486377.001]
  • [Cites] Hepatology. 1999 Oct;30(4):889-93 [10498639.001]
  • [Cites] Cancer. 1999 Oct 25;87(5):270-7 [10536352.001]
  • [Cites] Diagn Cytopathol. 1999 Dec;21(6):370-7 [10572267.001]
  • [Cites] Cancer. 1999 Dec 25;87(6):380-9 [10603192.001]
  • [Cites] Liver Transpl. 2000 Jan;6(1):67-72 [10648580.001]
  • [Cites] Acta Cytol. 2000 Mar-Apr;44(2):218-22 [10740609.001]
  • [Cites] Diagn Cytopathol. 2000 May;22(5):293-8 [10790236.001]
  • [Cites] Hepatogastroenterology. 2000 Mar-Apr;47(32):522-7 [10791228.001]
  • [Cites] Adv Anat Pathol. 2000 Jul;7(4):230-9 [10907808.001]
  • [Cites] Acta Cytol. 2000 Jul-Aug;44(4):515-23 [10934942.001]
  • [Cites] J Hepatol. 2000 Aug;33(2):282-9 [10952246.001]
  • [Cites] J Gastroenterol. 2000;35(8):641-5 [10955605.001]
  • [Cites] Cytopathology. 2000 Aug;11(4):262-7 [10983726.001]
  • [Cites] Diagn Cytopathol. 2000 Nov;23(5):326-8 [11074627.001]
  • [Cites] Histopathology. 2001 Feb;38(2):167-74 [11207830.001]
  • [Cites] Gut. 2001 Mar;48(3):440 [11256362.001]
  • [Cites] Pathology. 2001 May;33(2):130-41 [11358043.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):603-5 [11394662.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):254-8 [11580148.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1297-303 [11688465.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Acta Cytol. 2002 May-Jun;46(3):567-70 [12040655.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):978-88 [12170084.001]
  • [Cites] J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S101-8 [12394213.001]
  • [Cites] Diagn Cytopathol. 2002 Nov;27(5):298-302 [12411997.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1279-87 [12481008.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Acta Cytol. 2003 Jan-Feb;47(1):16-26 [12585026.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):332-6 [12789910.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):581-9 [12920750.001]
  • [Cites] Radiology. 1992 Jun;183(3):787-8 [1316621.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):799-808 [14526683.001]
  • [Cites] Diagn Cytopathol. 2004 Jan;30(1):1-6 [14696137.001]
  • [Cites] Diagn Cytopathol. 2004 Feb;30(2):92-7 [14755758.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S3-8 [14762831.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S9-15 [14762832.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S26-9 [14762835.001]
  • [Cites] Acta Cytol. 1991 Nov-Dec;35(6):661-70 [1659093.001]
  • [Cites] Diagn Cytopathol. 1990;6(4):275-9 [1698598.001]
  • (PMID = 15941489.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1177974
  •  go-up   go-down


Advertisement
4. Shah OJ, Robbani I, Nazir P, Khan AB: Central pancreatectomy: a new technique for resection of selected pancreatic tumors. Hepatobiliary Pancreat Dis Int; 2009 Feb;8(1):93-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For small benign tumors enucleation is not usually feasible due to their size and localization; then pancreatectomy is often needed.
  • Central pancreatectomy consists of a limited resection of the midportion of the pancreas and can be offered in benign and low-grade malignant tumors of the neck of the pancreas.
  • RESULTS: Four patients, two with serous cystadenoma, and one with an islet cell tumor, and one with a hydatid cyst, were identified for the procedure.
  • The mean tumor size was 3 cm, the mean operative time was 217.5 minutes, and the mean blood loss was 382.5 ml.
  • CONCLUSIONS: Central pancreatectomy is a procedure that offers excellent results in benign and low-grade malignant tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208523.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Arnold RS, He J, Remo A, Ritsick D, Yin-Goen Q, Lambeth JD, Datta MW, Young AN, Petros JA: Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1. Am J Pathol; 2007 Dec;171(6):2021-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased ROS and tumor growth in the Nox1-overexpressing DU145 cells were reversed in the presence of the Nox1RNAi.
  • Tumor (86%) was significantly more likely to have Nox1 staining than benign prostate tissue (62%) (P = 0.0001).
  • These studies indicate that Nox1 overexpression may function as a reversible signal for cellular proliferation with relevance for a common human tumor.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2004 Jun;84(6):785-95 [15107801.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):79-82 [10485709.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4614-21 [15269132.001]
  • [Cites] Exp Cell Res. 2004 Nov 1;300(2):455-62 [15475009.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):983-6 [8392985.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):16-22 [7820952.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Biochem Soc Trans. 1996 Nov;24(4):1028-32 [8968506.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):200-7 [15389790.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Feb;288(2):C450-7 [15469954.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Mar;288(3):C494-506 [15692148.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93 [15701844.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1198-202 [15709189.001]
  • [Cites] Cancer Lett. 2005 Apr 18;221(1):97-104 [15797632.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3017-24 [15833826.001]
  • [Cites] Mol Ther. 2005 May;11(5):724-33 [15851011.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4134-46 [15899804.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5719-23 [10582690.001]
  • [Cites] Circ Res. 2000 Mar 17;86(5):494-501 [10720409.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):667-72 [10874672.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Jun;297(3):1144-51 [11356940.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4386-92 [11389065.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):715-20 [11805326.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):143-54 [11900990.001]
  • [Cites] J Immunol. 2002 Jul 1;169(1):469-75 [12077278.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1225-33 [12599229.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):344-50 [12607603.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2513-22 [14633623.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9389-404 [14645548.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8758-73 [14647471.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1844-54 [14966267.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2197-205 [14767470.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3580-5 [15150115.001]
  • [Cites] Prostate. 2005 Jun 15;64(1):40-9 [15651067.001]
  • [Cites] J Pathol. 2005 Oct;207(2):164-76 [16086438.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31859-69 [15994299.001]
  • [Cites] BMC Cancer. 2005;5:108 [16111498.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1062-4 [9734401.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1186-96 [9797374.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879-84 [10359807.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9671-6 [10449752.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2373-9 [10483994.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1464-5 [14962934.001]
  • (PMID = 18055552.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA098912; United States / NCI NIH HHS / CA / R01 CA096994; United States / NCI NIH HHS / CA / CA098912; United States / NCI NIH HHS / CA / CA96994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cav1 protein, mouse; 0 / Caveolin 1; 0 / Interleukin-8; 0 / Proto-Oncogene Proteins c-fos; 0 / RNA, Small Interfering; 0 / Reactive Oxygen Species; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.99.- / NADPH oxidase 1
  • [Other-IDs] NLM/ PMC2111124
  •  go-up   go-down


6. Reid BJ: Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark; 2010;9(1-6):307-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus is a condition in which the stratified squamous epithelium of the distal esophagus is replaced by specialized intestinal metaplasia.
  • Clinical management of Barrett's esophagus, like many other "premalignant" conditions, is characterized by overdiagnosis of benign early changes that will not cause death or suffering during the lifetime of an individual and underdiagnosis of life-threatening early disease.
  • Specialized intestinal metaplasia has many properties that appear to be protective adaptations to the abnormal environment of gastroesophageal reflux.
  • Small, spatial scale studies have been used to infer the temporal order in which genomic abnormalities develop during neoplastic progression in Barrett's esophagus.
  • These spatial studies have provided the basis for prospective cohort studies of biomarkers, including DNA content abnormalities (tetraploidy, aneuploidy) and a biomarker panel of 9p LOH, 17p LOH and DNA content abnormalities.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1186-96 [17287898.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Hum Pathol. 1992 May;23(5):479-82 [1568744.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2946-50 [1581911.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(10):703-10 [1816011.001]
  • [Cites] Gut. 1992 May;33(5):587-91 [1351861.001]
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1769-76 [1360434.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):648-51 [8119224.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2292-5 [8162566.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1589-95 [8194706.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):151-5 [7816807.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1766-8 [7827934.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:577-83 [7587115.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):334-9; discussion 339-41 [11515862.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1179-86 [12439111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):53-61 [3354644.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):65-71 [2911184.001]
  • [Cites] Lab Invest. 1989 Mar;60(3):418-32 [2927081.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):815-20 [2777038.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6332-40 [17452981.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7 [18199717.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):510-22 [18400571.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1280-1 [18772403.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2331-6 [18729198.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] PLoS One. 2008;3(11):e3809 [19043591.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):814-8 [10570342.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95 [10601379.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1702-10 [10815888.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1126-37 [10958631.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3164-70 [11306503.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):302-6 [14566848.001]
  • [Cites] Mod Pathol. 2004 May;17(5):588-96 [15017433.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3084-92 [16407829.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6637-42 [17121882.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Oct 15;42(2):281-6 [2790761.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):259-63 [8542577.001]
  • [Cites] Oncogene. 1996 May 2;12(9):1873-8 [8649847.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4499-502 [8813147.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):298-304 [8816585.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1867-73 [8934532.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):515-31 [9210354.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1653-9 [9349498.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):641-51 [9708926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):950-7 [9764589.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Oct 1;106(1):11-7 [9772903.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1862-7 [10430093.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):221-30 [15617840.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):751-60 [15720801.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):830-4 [15824152.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):584-91 [15825175.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] J Pathol. 2006 Jan;208(1):100-7 [16278815.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6293-300 [17975140.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Gastroenterology. 1987 Jul;93(1):1-11 [3582897.001]
  • [Cites] Am J Gastroenterol. 1987 Oct;82(10):1012-5 [3661507.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • (PMID = 22112482.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01CA91955
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS578448; NLM/ PMC4026269
  •  go-up   go-down


7. Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, Bjartell A: Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One; 2009;4(11):e7953
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystatin C is believed to prevent tumor progression by inhibiting the activities of a family of lysosomal cysteine proteases.
  • In the present study, we examined the expression of cystatin C and its association with matrix metalloproteinases 2 (MMP2) and androgen receptor (AR) in a tissue microarray comparing benign and malignant specimens from 448 patients who underwent radical prostatectomy for localized prostate cancer.
  • Cystatin C expression was significantly lower in cancer specimens than in benign tissues (p<0.001) and there was a statistically significant inverse correlation between expression of cystatin C and MMP2 (r(s) (2) = -0.056, p = 0.05).
  • This suggests that cystatin C may mediate tumor cell invasion by modulating the activity of MAPK/Erk cascades.
  • [MeSH-minor] Cell Line, Tumor. Disease-Free Survival. Humans. Male. Matrix Metalloproteinase 2 / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Small Interfering / metabolism. Time Factors. Treatment Outcome


8. Bielinska M, Parviainen H, Kiiveri S, Heikinheimo M, Wilson DB: Review paper: origin and molecular pathology of adrenocortical neoplasms. Vet Pathol; 2009 Mar;46(2):194-210
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although there are unanswered questions about the origin and evolution of adrenocortical neoplasms, analysis of human tumor specimens and animal models indicates that adrenocortical tumorigenesis involves both genetic and epigenetic alterations.
  • Chromosomal changes accumulate during tumor progression, and aberrant telomere function is one of the key mechanisms underlying chromosome instability during this process.
  • Many of the mutations associated with benign human adrenocortical tumors result in dysregulated cyclic adenosine monophosphate signaling, whereas key factors and/or signaling pathways associated with adrenocortical carcinomas include dysregulated expression of the IGF2 gene cluster, activation of the Wnt/beta-catenin pathway, and inactivation of the p53 tumor suppressor.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1713-20 [9589681.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4237-43 [9751505.001]
  • [Cites] Rev Reprod. 1998 Sep;3(3):155-63 [9829550.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):216-9 [9920087.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):730-5 [10022445.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1116-21 [10084604.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cell. 1999 May 14;97(4):527-38 [10338216.001]
  • [Cites] Pathobiology. 2007;74(5):285-90 [17890895.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):303-12 [17936556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18205-10 [17989225.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2968-87 [17761949.001]
  • [Cites] Endocrinology. 1949 Mar;44(3):274-7 [18115077.001]
  • [Cites] Hum Mol Genet. 2008 Jan 1;17(1):1-14 [17901045.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):157-64 [18156936.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):22-32 [17879353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20926-31 [18087038.001]
  • [Cites] Mol Cell Endocrinol. 2001 Dec 20;185(1-2):17-25 [11738790.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):58-63 [11790982.001]
  • [Cites] Am J Hum Genet. 2002 Mar;70(3):604-11 [11813134.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):592-7 [11850784.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):187-94 [11994739.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;968:222-39 [12119279.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3122-35 [12130578.001]
  • [Cites] Trends Endocrinol Metab. 2002 Jul;13(5):200-8 [12185666.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):149-55 [12204535.001]
  • [Cites] Endocrinology. 2002 Nov;143(11):4358-65 [12399432.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2746-53 [12456795.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3951-64 [12748296.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Development. 2003 Aug;130(16):3663-70 [12835383.001]
  • [Cites] Cell. 2008 Mar 21;132(6):945-57 [18358808.001]
  • [Cites] Mol Endocrinol. 2008 Apr;22(4):781-98 [18174356.001]
  • [Cites] Pharmacogenomics. 2008 Feb;9(2):215-34 [18370850.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1442-9 [18198226.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):227-33 [18438169.001]
  • [Cites] Horm Metab Res. 2008 Jun;40(6):391-7 [18401830.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2057-62 [18334586.001]
  • [Cites] J Clin Pathol. 2008 Jul;61(7):787-93 [18430754.001]
  • [Cites] Vet Pathol. 2008 Jul;45(4):439-42 [18587089.001]
  • [Cites] Development. 2008 Aug;135(15):2593-602 [18599507.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):3222-5 [18544621.001]
  • [Cites] Eur J Hum Genet. 2008 Oct;16(10):1245-53 [18431404.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Sep;69(3):367-73 [18419788.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5609-18 [10579324.001]
  • [Cites] Genes Dev. 1999 Dec 1;13(23):3115-24 [10601037.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):441-8 [10634422.001]
  • [Cites] Endocrinology. 2000 Sep;141(9):3127-36 [10965883.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4734-41 [11134136.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):153-4 [11175780.001]
  • [Cites] Eur J Endocrinol. 2001 Feb;144(2):163-8 [11182753.001]
  • [Cites] Hum Reprod. 2000 Dec;15 Suppl 5:68-86 [11263539.001]
  • [Cites] Eur J Clin Invest. 2000 Dec;30 Suppl 3:69-75 [11281373.001]
  • [Cites] Dev Dyn. 2001 Sep;222(1):26-39 [11507767.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • [Cites] World J Surg. 2001 Jul;25(7):905-13 [11572032.001]
  • [Cites] World J Surg. 2001 Jul;25(7):948-56 [11572037.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26572-9 [12732619.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):479-89 [12967339.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5308-19 [14500362.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1575-85 [14767469.001]
  • [Cites] Mol Cell Endocrinol. 2004 Feb 27;215(1-2):89-94 [15026179.001]
  • [Cites] Gen Comp Endocrinol. 2004 Jun;137(2):148-65 [15158127.001]
  • [Cites] Trends Endocrinol Metab. 2005 Jul;16(5):235-42 [15949953.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4366-70 [15855265.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3975-84 [15919738.001]
  • [Cites] Science. 2005 Aug 19;309(5738):1253-6 [16037417.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 30;335(3):925-36 [16105662.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Eur J Endocrinol. 2005 Oct;153(4):477-87 [16189167.001]
  • [Cites] Mol Hum Reprod. 2005 Sep;11(9):631-40 [16219628.001]
  • [Cites] Trends Endocrinol Metab. 2005 Dec;16(10):458-68 [16275119.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] J Med Genet. 2006 Jan;43(1):91-6 [16033918.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):14-21 [16234301.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):196-203 [16249277.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):782-90 [16254030.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):267-75 [16452501.001]
  • [Cites] Vet Pathol. 2006 Mar;43(2):97-117 [16537928.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):953-60 [16585961.001]
  • [Cites] Nucleic Acids Res. 2006;34(8):2408-17 [16682448.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1040-3 [16574405.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(11):4111-21 [16705164.001]
  • [Cites] J Med Genet. 2006 Jun;43(6):523-6 [16155190.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:335-41 [16869770.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Oct;101(2-3):87-96 [16891114.001]
  • [Cites] Horm Metab Res. 2006 Sep;38(9):549-55 [16981135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1295-303 [16949934.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2848-63 [16873442.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1997 Mar;27(2):381-99 [9076914.001]
  • [Cites] Eur J Endocrinol. 1997 Mar;136(3):296-303 [9100555.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1303-9 [9137490.001]
  • [Cites] Nature. 1997 Nov 20;390(6657):311-5 [9384387.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6410-6 [9497372.001]
  • [Cites] Gene Expr Patterns. 2007 Jan;7(1-2):72-81 [16920405.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):259-67 [17044021.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1088:319-34 [17192577.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):93-7 [17077135.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):844-50 [17289876.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):976-88 [17122075.001]
  • [Cites] Cancer Lett. 2007 Mar 18;247(2):353-5; author reply 356-8 [16750598.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:17-22 [17207921.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):392-6 [15241730.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):93-8 [15287021.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6144-51 [15342398.001]
  • [Cites] Arch Pathol. 1966 Feb;81(2):140-5 [5904094.001]
  • [Cites] Cancer Res. 1968 Feb;28(2):251-63 [4966937.001]
  • [Cites] Am J Vet Res. 1969 Apr;30(4):583-9 [5813021.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):277-82 [2312105.001]
  • [Cites] Cell. 1991 Feb 22;64(4):849-59 [1997210.001]
  • [Cites] Curr Opin Cell Biol. 1991 Jun;3(3):444-51 [1892656.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Apr;40(4):465-77 [7910530.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4927-32 [7915195.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Sep;23(3):671-91 [7805662.001]
  • [Cites] JAMA. 1995 Jul 26;274(4):324-30 [7609262.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):233-8 [7673852.001]
  • [Cites] Endocrinology. 1995 Nov;136(11):4872-9 [7588219.001]
  • [Cites] Mol Endocrinol. 1996 May;10(5):585-98 [8732689.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):441-58, x [15850852.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):881-90 [15865944.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2976-81 [15741269.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3773-9 [15741255.001]
  • [Cites] Mol Endocrinol. 1999 Aug;13(8):1267-84 [10446902.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1039-45 [10514385.001]
  • [Cites] Growth Factors. 2004 Sep;22(3):141-50 [15518237.001]
  • [Cites] J Anat. 1961 Jul;95:325-36 [13715481.001]
  • [Cites] Hum Mol Genet. 2005 Jan 1;14(1):113-23 [15537664.001]
  • [Cites] Semin Reprod Med. 2004 Nov;22(4):281-8 [15635496.001]
  • [Cites] Semin Reprod Med. 2004 Nov;22(4):327-36 [15635500.001]
  • [Cites] Endocr Res. 2004 Nov;30(4):555-65 [15666792.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):615-9 [15546904.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:10-6 [17240045.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:23-8 [17250952.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Science. 2007 Mar 30;315(5820):1850-3 [17395830.001]
  • [Cites] Mol Cell Endocrinol. 2007 Apr 15;269(1-2):38-45 [17337116.001]
  • [Cites] Nature. 2007 May 24;447(7143):433-40 [17522677.001]
  • [Cites] Development. 2007 Jun;134(12):2349-58 [17537799.001]
  • [Cites] Horm Metab Res. 2007 Jun;39(6):461-6 [17578765.001]
  • [Cites] Horm Metab Res. 2007 Jun;39(6):467-73 [17578766.001]
  • [Cites] Physiol Genomics. 2007 Jun 19;30(1):26-34 [17327493.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):924-31 [17581575.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):776-83 [17455252.001]
  • [Cites] Nat Struct Mol Biol. 2007 Aug;14(8):754-61 [17632522.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):370-3 [17671971.001]
  • [Cites] Vet Clin North Am Exot Anim Pract. 2008 Jan;11(1):125-37, vii [18165141.001]
  • [Cites] Am J Hum Genet. 2008 Jan;82(1):39-47 [18179883.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Dec;8(4):343-8 [17934868.001]
  • [Cites] Chromosome Res. 2007;15(8):1001-13 [18185984.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Feb;68(2):264-70 [17854394.001]
  • [Cites] Endocrinology. 2008 Feb;149(2):651-61 [18006632.001]
  • [Cites] PLoS Genet. 2008 Jan;4(1):e10 [18208333.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Feb;22(1):77-93 [18279781.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1314-22 [18063677.001]
  • (PMID = 19261630.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK075618-02; United States / NIDDK NIH HHS / DK / R01 DK075618-02; United States / NIDDK NIH HHS / DK / DK52574; United States / NIDDK NIH HHS / DK / DK075618; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NIDDK NIH HHS / DK / R01 DK075618; United States / NIDDK NIH HHS / DK / P30 DK052574-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 165
  • [Other-IDs] NLM/ NIHMS85359; NLM/ PMC2811968
  •  go-up   go-down


9. Kubota Y, Onmura Y, Ohji H, Kunii T, Shibasaki T, Nakada T, Tomita Y: p53 antibodies in the serum of patients with prostate cancer. Int Urol Nephrol; 2008;40(1):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Serum levels of p53-specific antibodies in patients with relapsed, newly diagnosed prostate cancer and in patients with benign prostate hyperplasia were quantified by an enzyme-linked immunoabsorbent assay.
  • RESULT: There was no significant difference (P=0.96) between the serum levels of p53-specific antibodies in patients with newly diagnosed prostate cancer and with benign prostatic hyperplasia.
  • However, the difference between T1c group and benign prostatic hyperplasia group was not significant (P=0.686).
  • The relapsed cancer group tended to have low levels of the antibodies, and, there was no significant difference between the relapsed prostate cancer group and the benign prostatic hyperplasia group (P=0.14).
  • CONCLUSION: The use of titers of p53-specific antibodies to make differential diagnosis between prostate cancer and benign prostatic hyperplasia might have no role, and the antibodies should not be used as a marker of prostate cancer by itself.
  • Because our study is based on small number of patients, further studies are necessary before its absolute validity can be determined.
  • [MeSH-major] Antibodies, Neoplasm / blood. Biomarkers, Tumor / blood. Prostatic Neoplasms / blood. Tumor Suppressor Protein p53 / immunology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):789-93 [1347085.001]
  • [Cites] Int J Cancer. 1987 Feb 15;39(2):185-9 [3542843.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 [221923.001]
  • [Cites] Gut. 1997 Mar;40(3):356-61 [9135525.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] J Virol. 1979 Aug;31(2):472-83 [225566.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):480-7 [8056443.001]
  • [Cites] J Urol. 1997 Dec;158(6):2278-83 [9366376.001]
  • [Cites] J Urol. 2004 Jan;171(1):182-6 [14665872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3439-42 [1373500.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):682-9 [12548611.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1359-66 [9626451.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4168-74 [1322237.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1894-9 [7933246.001]
  • [Cites] Mod Pathol. 1994 May;7(4):435-9 [8066072.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2534-9 [9874460.001]
  • [Cites] JAMA. 1993 May 26;269(20):2650-8 [8487449.001]
  • (PMID = 17619164.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Zhang Y, Linn D, Liu Z, Melamed J, Tavora F, Young CY, Burger AM, Hamburger AW: EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther; 2008 Oct;7(10):3176-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that the expression of the EBP1 gene was significantly decreased in prostate cancer tissues compared with benign prostate at both mRNA and protein levels.
  • Restoration of EBP1 expression in the hormone-refractory LNCaP C81 cell line led to an amelioration of the androgen-independent phenotype based on established biological criteria and a reduction in the expression of a cohort of AR target genes.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):483-90 [14755679.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Mar;39(3):171-84 [14732919.001]
  • [Cites] Oncogene. 2004 May 27;23(25):4454-65 [15064750.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):390-400 [7688182.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Exp Cell Res. 1995 Oct;220(2):434-45 [7556453.001]
  • [Cites] Oncogene. 1996 Jun 20;12(12):2535-47 [8700512.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):212-6 [9052472.001]
  • [Cites] Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30 [9072304.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):733-6 [9192902.001]
  • [Cites] Oncogene. 1997 Nov 27;15(22):2705-16 [9400997.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63 [10318905.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):517-27 [15542435.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):140-6 [15583694.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1704-12 [15755991.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3404-9 [15833875.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):249-59 [15834940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5 [15994225.001]
  • [Cites] Mol Carcinog. 2005 Sep;44(1):1-10 [16044418.001]
  • [Cites] Nucleic Acids Res. 2005;33(18):6024-33 [16254079.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1057-65 [16598187.001]
  • [Cites] Biochem J. 2006 May 15;396(1):99-107 [16396631.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2730-7 [16675564.001]
  • [Cites] EMBO J. 2006 May 17;25(10):2083-95 [16642037.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):675-84 [17634423.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):2005-12 [17641068.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8253-61 [16278481.001]
  • [Cites] Urology. 1999 Nov;54(5):839-45 [10565744.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):321-9 [10797306.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6841-5 [11156376.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7408-12 [11606371.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 23;289(1):240-4 [11708806.001]
  • [Cites] Prostate. 2002 Mar 1;50(4):222-35 [11870800.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5609-18 [12165860.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5485-8 [12359757.001]
  • [Cites] Gene. 2003 Jan 2;302(1-2):11-9 [12527192.001]
  • [Cites] Prostate. 2003 May 1;55(2):147-57 [12661040.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):552-6 [12888829.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3320-8 [12960118.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):478-85 [14506750.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Pathol. 2004 Jun;203(2):688-95 [15141384.001]
  • (PMID = 18852121.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076047-06; United States / NCI NIH HHS / CA / CA088882-01; United States / NCI NIH HHS / CA / R21 CA088882-02; United States / NCI NIH HHS / CA / R01 CA076047-08; United States / NCI NIH HHS / CA / R01 CA076047-06; United States / NCI NIH HHS / CA / CA076047-07; United States / PHS HHS / / R21 088882-01; United States / NCI NIH HHS / CA / CA076047-08; United States / NCI NIH HHS / CA / R21 CA088882-01; United States / NCI NIH HHS / CA / R01 CA76047; United States / NCI NIH HHS / CA / CA088882-02; United States / NCI NIH HHS / CA / R01 CA076047; United States / NCI NIH HHS / CA / R21 CA088882; United States / NCI NIH HHS / CA / R01 CA076047-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Androgens; 0 / Neuregulin-1; 0 / PA2G4 protein, human; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS79579; NLM/ PMC2629587
  •  go-up   go-down


11. Sakamoto A, Yoshida T, Matsuura S, Tanaka K, Matsuda S, Oda Y, Hori Y, Yokomizo A, Iwamoto Y: Metastasis to the gluteus maximus muscle from renal cell carcinoma with special emphasis on MRI features. World J Surg Oncol; 2007;5:88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic RCC must be differentiated from benign primary soft-tissue tumors because aggressive surgical resection is necessary.
  • Retrospectively, the small mass (1 cm in diameter) was overlooked 5 years earlier on enhanced CT.
  • Because the growth of the lesion was slow, benign tumor was a differential diagnosis.
  • Therefore, under a diagnosis of metastatic RCC, the lesion was resected together with the surrounding skeletal muscle.
  • CONCLUSION: MRI features of metastatic RCC may be beneficial in differentiating it from primary soft-tissue tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1623-8 [10845496.001]
  • [Cites] Skeletal Radiol. 2000 Apr;29(4):187-95 [10855466.001]
  • [Cites] J Orthop Sci. 2001;6(2):189-92 [11484108.001]
  • [Cites] Acta Chir Belg. 2002 Oct;102(5):351-2 [12471771.001]
  • [Cites] J Ultrasound Med. 2005 Oct;24(10):1419-23; quiz 1424-5 [16179627.001]
  • [Cites] Eur Urol. 1991;20(2):167-9 [1752278.001]
  • [Cites] J Urol. 1996 Jul;156(1):173 [8648786.001]
  • [Cites] Tumori. 1990 Aug 31;76(4):407-9 [2399572.001]
  • [Cites] Cancer. 1973 Nov;32(5):1030-42 [4131758.001]
  • [Cites] J Urol. 1981 Jul;126(1):17-23 [7253072.001]
  • [Cites] Skeletal Radiol. 1995 May;24(4):267-70 [7644939.001]
  • [Cites] Scand J Urol Nephrol. 1993;27(1):143-4 [8493466.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):247-62 [8493748.001]
  • [Cites] Int Surg. 1990 Jul-Sep;75(3):198-202 [2242976.001]
  • (PMID = 17683570.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1976113
  •  go-up   go-down


12. Zenmyo M, Ishido Y, Terahara M, Yamamoto T, Tanimoto A, Komiya S, Ijiri K: Intramedullary subependymoma of the cervical spinal cord: a case report with immunohistochemical study. Int J Neurosci; 2010 Oct;120(10):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spinal subependymomas, which have a relatively benign nature, are very rare tumors.
  • The diffused enlargement of the spinal cord at C2 level involved the lesion with isointensity on a T1-weighted MRI and relatively high intensity on a T2-weighted MRI.
  • Enhancement in the small part of the tumor was observed on a T1-weighted MRI with gadolinium administration.
  • The tumor occupied the left side of the spinal cord, and was totally removed through a laminoplasty of C2.
  • Immunohistochemistry was useful for pathological diagnosis.

  • Genetic Alliance. consumer health - Subependymoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942580.001).
  • [ISSN] 1563-5279
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Saintigny P, Coulon S, Kambouchner M, Ricci S, Martinot E, Danel C, Breau JL, Bernaudin JF: Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma. Int J Cancer; 2005 Jul 10;115(5):777-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma.
  • Metastatic lymph nodes (LNs) are the major prognostic factor in resected non small cell lung carcinoma (NSCLC).
  • Forty-three NSCLC tumor samples, 4 micrometastatic, 6 metastatic and 84 histologically negative mediastinal LNs from 19 patients with NSCLC were evaluated as well as blood mononuclear cells from 29 healthy volunteers and 17 benign LNs.
  • All tumor samples were positive for at least 1 marker and 74% of samples were positive for all 3 markers.
  • CK7 and CK19 mRNA were not detected in benign LN and blood cells from healthy donors in contrast with MUC1 mRNA.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Keratins / biosynthesis. Keratins / genetics. Lung Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Mucin-1 / biosynthesis. Mucin-1 / genetics
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Male. Middle Aged. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15729695.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Mucin-1; 0 / RNA, Messenger; 68238-35-7 / Keratins
  •  go-up   go-down


14. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, Cunha GR: Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer; 2006 May 1;118(9):2123-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In [T+E2]-implanted mice, mUGM+BPH-1 TRs formed carcinomas that contained a fibrous connective tissue stroma permeating the tumor; smooth muscle when present was associated with vasculature.
  • Epithelial cells isolated from untreated mUGM+BPH-1 TRs exhibited benign histology and formed small nontumorigenic grafts when subsequently transplanted into athymic nude mice.
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Disease Progression. Epithelial Cells / physiology. Humans. Male. Mesoderm. Mice. Mice, Nude. Neoplasm Metastasis. Prostate / cytology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16331600.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG0026604; United States / NCI NIH HHS / CA / CA84294; United States / NCI NIH HHS / CA / CA89520; United States / NCI NIH HHS / CA / CA96403; United States / NCI NIH HHS / CA / CA97725-01; United States / NICHD NIH HHS / HD / HD007263; United States / NCI NIH HHS / CN / N01CN15114-MAO; United States / NCI NIH HHS / CA / U01 CA96403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol
  •  go-up   go-down


15. Cao D, Tsangaris TN, Kouprina N, Wu LS, Balch CM, Vang R, Argani P: The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling. Ann Surg Oncol; 2008 May;15(5):1330-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 168 SSMs with a small, additional superficial margin (ASM) specimen taken directly over the tumor to the dermis intraoperatively were studied.
  • ASM sampling rendered the final true margin directly over the tumor negative in 54 of 58 (93%) SSMs with a focally positive superficial specimen margin, but did not negate the nonfocally positive superficial specimen margin in six other cases.
  • In SSMs with a positive superficial specimen margin, multivariate analysis revealed that the presence of extensive ductal carcinoma in situ (DCIS) in the SSM and a thicker ASM specimen were the only independent factors predictive of residual breast carcinoma in ASM.
  • Eighty-nine (53%) ASMs contained benign breast tissue.
  • CONCLUSIONS: Superficial specimen margins in SSMs are often microscopically positive and approximately half of ASMs contain benign breast tissue, likely reflecting the difficulty in completely removing breast tissue near the skin flaps in SSMs.
  • ASM sampling effectively decreases positive superficial specimen margins directly over the tumor in SSMs, but fails to account for positive superficial specimen margins in other quadrants in patients with multicentric disease, especially extensive DCIS.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1999 Aug;104(2):421-5 [10654685.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):438-43 [17826052.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1619-25 [11920520.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):814-9 [12035037.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):706-11 [12560691.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):712-20; discussion 721-2 [12560692.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):102-7 [12620902.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):108-12 [12620903.001]
  • [Cites] Am J Surg. 2004 Jul;188(1):78-84 [15219490.001]
  • [Cites] Surg Gynecol Obstet. 1966 Mar;122(3):529-40 [5908662.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):284-7 [6830336.001]
  • [Cites] Plast Reconstr Surg. 1991 Jun;87(6):1048-53 [1852020.001]
  • [Cites] Plast Reconstr Surg. 1991 Sep;88(3):389-92; discussion 393-4 [1871214.001]
  • [Cites] Am J Clin Pathol. 1992 Jul;98(1):125-37 [1615916.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1746-51 [8082077.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):411-6 [8790856.001]
  • [Cites] Ann Surg. 1997 May;225(5):570-5; discussion 575-8 [9193184.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1740-5 [9351542.001]
  • [Cites] Plast Reconstr Surg. 1998 Jul;102(1):49-62 [9655407.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):456-63 [9718177.001]
  • [Cites] Ann Surg Oncol. 1998 Oct-Nov;5(7):620-6 [9831111.001]
  • [Cites] Breast. 2004 Dec;13(6):488-93 [15563856.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):606-8 [16164932.001]
  • [Cites] Breast J. 2005 Sep-Oct;11(5):374-5 [16174169.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1625-32 [16327435.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1037-44 [16244800.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Int J Clin Oncol. 2006 Feb;11(1):51-4 [16508729.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):1074-8; discussion 1078-80 [17481544.001]
  • [Cites] Cancer J. 2000 Sep-Oct;6(5):331-5 [11079173.001]
  • (PMID = 18246402.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; None / None / / P50 CA088843-06A19005; United States / NCI NIH HHS / CA / P50 CA088843-06A19005
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS243747; NLM/ PMC2958107
  •  go-up   go-down


16. Sieunarine K, Cowie AS, Bartlett JD, Lindsay I, Smith JR: A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):671-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique.
  • Adenomatoid tumors of the uterus are uncommon benign lesions derived from mesothelium, with a prevalence of 1.2% in one study of 1 000 unselected hysterectomy specimens.
  • They are usually small and near the serosal surface; however, they may be large and diffuse (giant adenomatoid tumors).
  • This transpired to be an adenomatoid tumor, and she underwent three transcervical resections of the tumor (TCRT) over a period of 12 months for tumor recurrence and failure of symptom resolution.
  • A specialist opinion on the suitability of vascular embolization of the tumor judged that it would be ineffective for this lesion.
  • She then underwent a Strassman procedure and removal of the adenomatoid tumor.
  • This involved dissection of ureters and pelvic vasculature, selective temporary ligation of uterine arteries, hemisection of the uterus, and excision of the tumor with frozen sections to ensure clear tumor margins and resuturing of the uterine halves.
  • Temporary vascular occlusion of the uterine arteries and ovarian vessels allowed a Strassman procedure, which resulted in successful resection of a recurrent giant adenomatoid tumor of the uterus, with fertility preservation in a young nulliparous woman.
  • Two and a half years on there is no evidence of tumor recurrence.
  • [MeSH-major] Adenomatoid Tumor / surgery. Gynecologic Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Uterine Neoplasms / surgery. Uterus / blood supply

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014122.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C: Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Childs Nerv Syst; 2005 Aug;21(8-9):747-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma (CP) is the most common intracranial non-glial tumour observed in pediatric age.
  • Although histologically benign and amenable to surgical treatment, its location and relation with vital nervous and vascular structures makes the feasibility of a radical resection difficult even in the microneurosurgery era.
  • Beside the difficulties experienced when performing tumour resection, post-operative complications, such as endocrinological imbalance, represent another point that makes CP total excision a challenge.
  • In order to avoid such complications, some authors have suggested to renounce to radical resection and to rely on post-operative radiation therapy to minimise the risk of residual tumour progression.
  • The tumour was managed by means of a single surgical approach in 47 cases and with a two-stage operation in the remaining five cases.
  • Radical tumour resection was achieved in 40 cases, subtotal (only small tumour remnants adherent to the carotid arteries, 3rd ventricle floor or visual pathways) in nine, and only partial in the remaining three cases RESULTS: Histology demonstrated the adamantinous variant in all cases.
  • Twelve patients underwent radiotherapy, six after an initially incomplete tumour resection and six following relapse.
  • Although not insignificant, post-operative mortality and morbidity do not seem to represent a major contraindication in attempting a radical tumour resection whenever possible.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 1980 Nov;97(5):728-35 [7431164.001]
  • [Cites] Neurosurgery. 1982 Sep;11(3):382-9 [7133354.001]
  • [Cites] J Neurosurg. 1986 Jul;65(1):22-7 [3712025.001]
  • [Cites] Dev Med Child Neurol. 2004 Apr;46(4):220-9 [15077699.001]
  • [Cites] Childs Nerv Syst. 2002 Oct;18(9-10):468-73 [12382167.001]
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):533-41 [11013625.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] Soc Work Health Care. 2003;38(1):81-107 [14984250.001]
  • [Cites] Childs Nerv Syst. 1990 Jan;6(1):13-7 [2311109.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14 (5):e13 [15669809.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):715-24 [7596502.001]
  • [Cites] Pediatr Neurosurg. 2001 Mar;34(3):166-7 [11359106.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):714-20 [14967425.001]
  • [Cites] Pediatr Neurosurg. 2003 Jul;39(2):97-103 [12845200.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:335-40 [3628815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):189-95 [8407391.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5435-40 [15531494.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:47-56 [11143262.001]
  • [Cites] Cancer J. 2001 Nov-Dec;7(6):516-20 [11769865.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):69-78 [11949829.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Jun;16(5):703-10 [12880119.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Neurochirurgie. 2002 Sep;48(4):309-18 [12407316.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1053-7; discussion 1057-8 [11846897.001]
  • [Cites] Surg Neurol. 2002 Jan;57(1):25-33 [11834269.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):611-7 [1429082.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75(6):889-92 [15146007.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):47-52 [1727168.001]
  • [Cites] Med Pediatr Oncol. 2003 Aug;41(2):123-7 [12825216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1313-21 [2689398.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Feb;15(1):10-3 [12602548.001]
  • [Cites] Klin Padiatr. 2003 Nov-Dec;215(6):310-4 [14677094.001]
  • [Cites] Pediatr Neurosurg. 1993;19(1):6-14 [8422329.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(5):447-54 [9728244.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3):445-51 [15035280.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):492-9 [12243827.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):241-7; discussion 248 [11118571.001]
  • (PMID = 15995885.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Vescovi P, Corcione L, Meleti M, Merigo E, Fornaini C, Manfredi M, Bonanini M, Govoni P, Rocca JP, Nammour S: Nd:YAG laser versus traditional scalpel. A preliminary histological analysis of specimens from the human oral mucosa. Lasers Med Sci; 2010 Sep;25(5):685-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperplastic fibro-epithelial lesions are the most common tumor-like swellings in the mouth.
  • Some controversies of laser surgery concern the accuracy of pathological diagnosis as well as the control of thermal damage on the target tissue.
  • The aim of this study was to establish if the thermal changes induced by the Nd:YAG laser may affect the histopathological diagnosis and the evaluation of the resection margins.
  • Furthermore, we compared the histological features of oral benign fibro-epithelial lesions excised through Nd:YAG laser and traditional scalpel.
  • Twenty-six benign fibro-epithelial oral lesions from 26 patients, localized in the same oral subsites (cheek and buccal mucosa), were collected at the Unit of Oral Pathology and Oral Laser-assisted Surgery of the Academic Hospital of the University of Parma, Italy.
  • Group 1 included six specimens excised through Nd:YAG laser with an output power of 3.5 W and a frequency of 60 Hz (power density 488,281 W/cm2); Group 2 included nine specimens excised through Nd:YAG laser with an output power of 5 W and a frequency of 30 Hz; Group 3 included 11 specimens excised through a Bard-Parker scalpel blade no. 15c.
  • Nd:YAG laser induced serious thermal effects in small specimens (mean size less than 7 mm) independently from the frequency and power employed.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photomed Laser Surg. 2007 Oct;25(5):381-92 [17975951.001]
  • [Cites] Am J Vet Res. 2005 Mar;66(3):500-5 [15822596.001]
  • [Cites] Laryngoscope. 2003 Feb;113(2):228-36 [12567074.001]
  • [Cites] Int J Periodontics Restorative Dent. 2007 Dec;27(6):577-87 [18092452.001]
  • [Cites] J Periodontol. 1998 Nov;69(11):1278-82 [9848538.001]
  • [Cites] Lasers Surg Med. 1997;21(3):248-54 [9291081.001]
  • [Cites] J Craniomaxillofac Surg. 2006 Jan;34(1):17-24 [16352435.001]
  • [Cites] Eur J Paediatr Dent. 2008 Mar;9(1):13-7 [18380525.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Mar;116(3):379-85 [9121794.001]
  • [Cites] J Clin Laser Med Surg. 1992 Apr;10(2):109-13 [10146194.001]
  • [Cites] J Gynecol Surg. 1994 Winter;10(4):229-34 [10150434.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):764-73 [17095269.001]
  • [Cites] Obstet Gynecol. 1991 Jun;77(6):905-11 [2030866.001]
  • [Cites] Br Dent J. 2007 Feb 24;202(4):185-91 [17322842.001]
  • (PMID = 20393771.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Armah HB, Parwani AV: Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature. Diagn Pathol; 2007;2:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature.
  • BACKGROUND: Perivascular epithelioid cell tumor (PEComa), other than angiomyolipoma (AML), clear cell sugar tumor (CCST), and lymphangioleiomyomatosis (LAM), is a very rare mesenchymal tumor with an unpredictable natural history.
  • The uterus is the most prevalent reported site of involvement of PEComa-not otherwise specified (PEComa-NOS).
  • To the best of our knowledge, about 100 PEComa-NOS have been reported in the English Language medical literature, of which 38 were uterine PEComa-NOS.
  • These reported cases of uterine PEComa-NOS have usually shown clinically benign behavior, but 13 tumors, three of them associated with tuberous sclerosis complex (TSC), exhibited local aggressive behavior and four of them showed distant metastases.
  • CASE PRESENTATION: We report the case of a 59-year-old woman, who presented with renal and pulmonary lesions seven years after the initial diagnosis of uterine leiomyosarcoma.
  • Histological and immunohistochemical analysis of the renal and pulmonary lesions, in addition to retrospective re-evaluation of the previous uterine tumor, led to the final diagnosis of malignant uterine PEComa with late renal and pulmonary metastases.
  • All three lesions had the typical histological appearance of PEComa-NOS showing a biphasic growth pattern with continuous transition between spindle cells and epithelioid cells, often arranged around vascular spaces.
  • Immunohistochemically, the tumor cells of both phenotypes in all three lesions stained for melanocytic (HMB-45 and Melan-A/MART-1) and myoid (desmin, smooth muscle actin, and muscle-specific actin/all muscle actin/HHF-35) markers.
  • CONCLUSION: The findings indicate that despite the small number of reported cases, PEComas-NOS should be considered tumors of uncertain malignant potential, and metastases to other organs might become evident even several years after the primary diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2001 Jun;14(6):563-8 [11406657.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):1-13 [11756764.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E96-8 [12562263.001]
  • [Cites] Pathol Res Pract. 2003;199(1):47-50 [12650518.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):627-8 [12890819.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):244-9 [15043315.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1230-2 [15316324.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):98-104 [15803216.001]
  • [Cites] Arch Pathol Lab Med. 2005 May;129(5):690-3 [15859645.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):307-8 [1599021.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):341-6 [16175079.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1558-75 [16327428.001]
  • [Cites] Pathol Res Pract. 2006;202(1):37-41 [16343800.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Dec;27(12):681-4 [16344678.001]
  • [Cites] Histopathology. 2006 Jan;48(1):75-82 [16359539.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):95-8 [17197924.001]
  • [Cites] Adv Anat Pathol. 2007 Jan;14(1):36-41 [17198309.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):199-202 [2025321.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):722-30 [8651352.001]
  • (PMID = 18053181.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2213634
  •  go-up   go-down


20. Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, Ulmert D, Lilja H, Ceder Y: miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer; 2010 Dec 15;127(12):2768-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
  • MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally regulate gene expression.
  • In this study, we show that miR-34c is downregulated in PCa (p = 0.0005) by performing qRT-PCR on 49 TURPs from PCa patients compared to 25 from patients with benign prostatic hyperplasia.
  • The miR-34c expression was found to inversely correlate to aggressiveness of the tumor, WHO grade, PSA levels and occurrence of metastases.
  • Our findings provide new insight into the role of miR-34c in the prostate, exhibiting tumor suppressing effects on proliferation, apoptosis and invasiveness.
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis. Blotting, Western. Cell Adhesion. Cell Differentiation. Cell Movement. Cell Proliferation. Down-Regulation. E2F3 Transcription Factor / genetics. E2F3 Transcription Factor / metabolism. Genes, bcl-2 / genetics. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Wound Healing


21. Chakrabarti J, Tekriwal R, Ganguli A, Ghosh S, Mishra PK: Pedicled buccal fat pad flap for intraoral malignant defects: A series of 29 cases. Indian J Plast Surg; 2009 Jan-Jun;42(1):36-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A buccal fat pad (BFP) as a flap for reconstruction of defects in the oral cavity has been described for a variety of benign conditions.
  • We describe the indications, advantages, and complications of the BFP flap and report our clinical experience with the flap for intraoral reconstruction after tumor removal.
  • From 2005 to 2008, we analyzed 29 patients in the age range of 32 to 82 years old who underwent a pedicled BFP flap reconstruction for oral defects after intraoral tumor removal.
  • Judicious use of buccal fat pad reconstruction offers a simple, convenient, and reliable way to reconstruct small to medium defects of the oral cavity with low morbidity, even in older patients who would not be able to tolerate time-consuming flap reconstruction procedures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Oral Maxillofac Surg. 2005 Apr;43(2):148-54 [15749216.001]
  • [Cites] J Laryngol Otol. 1999 Sep;113(9):834-8 [10664688.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Apr;35(2):81-4 [9146863.001]
  • [Cites] J Oral Maxillofac Surg. 1995 Jul;53(7):771-5; discussion 775-6 [7595791.001]
  • [Cites] Br J Oral Maxillofac Surg. 1995 Feb;33(1):40-2 [7718528.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Feb;22(1):2-6 [8459117.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Apr;49(4):413-6 [1848612.001]
  • [Cites] Morphol Embryol (Bucur). 1989 Apr-Jun;35(2):73-7 [2529432.001]
  • [Cites] J Oral Maxillofac Surg. 1988 Feb;46(2):100-6 [3276856.001]
  • [Cites] J Oral Maxillofac Surg. 1986 Jun;44(6):435-40 [3457926.001]
  • [Cites] Plast Reconstr Surg. 1990 Jan;85(1):29-37 [2293733.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Apr;55(4):349-50 [6574411.001]
  • [Cites] J Maxillofac Surg. 1977 Nov;5(4):241-4 [338848.001]
  • [Cites] Swiss Med Wkly. 2003 Aug 23;133(33-34):465-70 [14625814.001]
  • [Cites] Plast Reconstr Surg. 2002 Jun;109(7):2509-18; discussion 2519-20 [12045584.001]
  • [Cites] Head Neck. 2001 May;23(5):383-8 [11295812.001]
  • [Cites] J Craniomaxillofac Surg. 1998 Aug;26(4):267-71 [9777507.001]
  • (PMID = 19881018.001).
  • [ISSN] 1998-376X
  • [Journal-full-title] Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • [ISO-abbreviation] Indian J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2772293
  •  go-up   go-down


22. Gütgemann I, Haas S, Berg JP, Zhou H, Büttner R, Fischer HP: CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions. Virchows Arch; 2006 Apr;448(4):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions.
  • Twelve of 17 (70.5%) bile duct adenomas were CD56 positive, whereas von Meyenburg complexes expressed CD56 only very focally in less than 5% of lesional cells.
  • Thus, if van Meyenburg complexes are excluded, CD56 can be used to differentiate intrahepatic non-neoplastic from neoplastic proliferations, which is a helpful diagnostic tool in small liver biopsies.
  • [MeSH-major] Antigens, CD56 / metabolism. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Biomarkers, Tumor / metabolism. Cholangiocarcinoma / metabolism. Cholangitis / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Bile Duct / diagnosis. Adenoma, Bile Duct / metabolism. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Choledochal Cyst / diagnosis. Choledochal Cyst / metabolism. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Liver Cirrhosis / diagnosis. Liver Cirrhosis / metabolism

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(6):373-80 [1719697.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):858-64 [8669534.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1206-9 [9752860.001]
  • [Cites] Arch Pathol Lab Med. 1999 May;123(5):411-4 [10235499.001]
  • [Cites] Verh Dtsch Ges Pathol. 1995;79:36-46 [8600693.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1454-7 [14576479.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1599-612 [10793072.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):196-200 [9490284.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1019-25 [1700614.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1077-88 [15793288.001]
  • [Cites] Pathol Int. 2002 Apr;52(4):300-6 [12031086.001]
  • [Cites] Histochem Cell Biol. 2001 Sep;116(3):233-9 [11685552.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):64-70 [12866374.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1387-93 [11391527.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1548-9 [9865848.001]
  • (PMID = 16411132.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Cutress ML, Ratan HL, Williams ST, O'Brien MF: Update on the management of T1 renal cortical tumours. BJU Int; 2010 Oct;106(8):1130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are a range of treatment strategies for the management of patients with small incidental renal cortical tumours including active surveillance, radiofrequency ablation, cryotherapy, radical nephrectomy and partial nephrectomy.
  • A large number of such tumours are benign and might therefore be over-treated with radical nephrectomy.
  • [MeSH-minor] Disease Progression. Humans. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738293.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


24. Redjimi N, Gaudin F, Touboul C, Emilie D, Pallardy M, Biola-Vidamment A, Fernandez H, Prévot S, Balabanian K, Machelon V: Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer. Mol Cancer; 2009;8:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.
  • BACKGROUND: Little is known about the molecules that contribute to tumor progression of epithelial ovarian cancer (EOC), currently a leading cause of mortality from gynecological malignancies.
  • The objectives of the current study were to examine the expression of GILZ in EOC and its effect on tumor cell proliferation.
  • RESULTS: GILZ expression was measured by immunohistochemical staining in tissue sections from 3 normal ovaries, 7 benign EOC and 50 invasive EOC.
  • GILZ was not detected on the surface epithelium of normal ovaries and benign tumors.
  • In contrast, it was expressed in the cytoplasm of tumor cells in 80% EOC specimens.
  • They were also higher in tumor cells containing large amounts of phosphorylated protein kinase B (p-AKT) (unpaired t test, P < 0.0001).
  • To assess the effect of GILZ on proliferation and AKT activation, we used the BG-1 cell line derived from ovarian tumor cells as a cellular model.
  • GILZ expression was either enhanced by stable transfection or decreased by the use of small interfering (si) RNA targeting GILZ.


25. Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL: Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer; 2008 Feb 15;122(4):807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have performed cDNA microarray analyses to identify gene expression differences between highly invasive glioblastoma multiforme (GBM) and typically benign pilocytic astrocytomas (PA).
  • Despite the significant clinical and pathological differences between the 2 tumor types, only 63 genes were found to exhibit 2-fold or greater overexpression in GBM as compared to PA.
  • In the examination of more than 100 tumors of the central nervous system, we found progressively higher expression of MELK with astrocytoma grade and a noteworthy uniformity of high level expression in GBM.
  • [MeSH-minor] Adult. Apoptosis. Brain / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cell Proliferation. Child. DNA Methylation. Gene Dosage. Humans. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960622.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / MELK protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


26. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z: Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol; 2006 Dec;169(6):2199-208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better understand the mechanisms of STAT3 regulation in benign and malignant prostate, we have investigated the role of suppressor of cytokine signaling (SOCS)-3.
  • SOCS-3 immunohistochemistry revealed a negative or weak reaction in benign areas, whereas its expression was detected in tumor tissue.
  • [MeSH-minor] Apoptosis. Cell Line, Tumor. Cell Proliferation. Humans. Interleukin-3 / metabolism. Janus Kinases / metabolism. Male. Methylation. RNA, Small Interfering. STAT3 Transcription Factor / metabolism. Suppressor of Cytokine Signaling 3 Protein. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7777-83 [10075669.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 [14617776.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10749-58 [15653674.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2114-20 [15688010.001]
  • [Cites] Prostate. 2000 Jan;42(1):1-7 [10579793.001]
  • [Cites] Prostate. 2000 Feb 1;42(2):88-98 [10617865.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):186-95 [10639189.001]
  • [Cites] J Pathol. 2000 Jul;191(3):239-44 [10878544.001]
  • [Cites] Leukemia. 2005 Feb;19(2):209-13 [15618960.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):106-13 [12953803.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):11-20 [14749471.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4774-82 [15256446.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1449-60 [15509516.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Mol Endocrinol. 1992 Jan;6(1):15-25 [1738367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3556-60 [1373503.001]
  • [Cites] Urology. 1995 Mar;45(3):542-9 [7879350.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4640-5 [9788616.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):213-8 [9892209.001]
  • [Cites] Pediatr Nephrol. 2005 May;20(5):567-75 [15723195.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):47-53 [11391686.001]
  • [Cites] Nat Med. 2005 Aug;11(8):892-8 [16007096.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):551-60 [15929083.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6406-17 [16007195.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6699-708 [16007169.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2502-12 [16199153.001]
  • [Cites] Endocrinology. 2006 Aug;147(8):3809-17 [16709613.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):209-16 [15712220.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 11;278(1):38-43 [11071852.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3749-63 [11014231.001]
  • [Cites] Prostate. 2001 Aug 1;48(3):188-99 [11494334.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2941-8 [11555613.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1880-90 [11682619.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8471-82 [11713282.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2159-65 [11733366.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 11;290(1):249-55 [11779161.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):339-45 [11786427.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):241-6 [11987152.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5632-6 [12384515.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6659-66 [12438264.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):233-41 [12507906.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):655-63 [12547723.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):594-600 [12576423.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1247-52 [12606952.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1631-43 [12639948.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27287-92 [12719422.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):524-32 [12888825.001]
  • (PMID = 17148681.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-3; 0 / RNA, Small Interfering; 0 / SOCS3 protein, human; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Suppressor of Cytokine Signaling 3 Protein; 0 / Suppressor of Cytokine Signaling Proteins; E0399OZS9N / Cyclic AMP; EC 2.7.10.2 / Janus Kinases
  • [Other-IDs] NLM/ PMC1762483
  •  go-up   go-down


27. Moore AB, Yu L, Swartz CD, Zheng X, Wang L, Castro L, Kissling GE, Walmer DK, Robboy SJ, Dixon D: Human uterine leiomyoma-derived fibroblasts stimulate uterine leiomyoma cell proliferation and collagen type I production, and activate RTKs and TGF beta receptor signaling in coculture. Cell Commun Signal; 2010;8:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine leiomyomas (fibroids) are benign smooth muscle tumors that often contain an excessive extracellular matrix (ECM).
  • There was also increased secretion of vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor-2, and platelet derived growth factor A and B in the media of UtLM cells cocultured with FB.
  • The downstream effectors phospho-small mothers against decapentaplegic -2 and -3 protein (SMAD) levels were also increased in cocultured UtLM cells.
  • The soluble factors released by tumor-derived fibroblasts and/or UtLM cells, and activation of the growth factor receptors and their pathways stimulated the proliferation of UtLM cells and enhanced the production of ECM proteins.
  • CONCLUSIONS: These data support the importance of interactions between fibroid tumor cells and ECM fibroblasts in vivo, and the role of growth factors, and ECM proteins in the pathogenesis of uterine fibroids.


28. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Böhling T: Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol; 2005 Mar;58(3):297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Merkel cell carcinoma (MCC) is a rare malignant cutaneous neuroendocrine tumour that mostly affects the elderly.
  • It shows rapid progression of the primary tumour, together with a vertical growth pattern into the underlying subcutaneous tissue.
  • Tenascin-C (Tn-C) is a large extracellular matrix glycoprotein that is expressed in various benign and malignant processes.
  • The expression of Tn-C correlated significantly with large tumour size.
  • Most of the Tn-C negative samples were of small size.
  • CONCLUSIONS: Tn-C expression seems to increase with tumour size and malignant behaviour.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Merkel Cell / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism. Tenascin / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):58-62 [10665914.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Forensic Sci Int. 2002 Apr 18;126(2):118-22 [12084487.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3051-6 [12926160.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] APMIS. 2004 Jan;112(1):39-44 [14961973.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4587-91 [14981900.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Sci Am. 1986 Jun;254(6):42-51 [3010451.001]
  • [Cites] Dev Biol. 1988 Aug;128(2):245-55 [2456233.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Br J Dermatol. 1991 Jan;124(1):13-20 [1704250.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):811-6 [1707033.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1143-50 [1719820.001]
  • [Cites] Invasion Metastasis. 1991;11(6):325-31 [1726610.001]
  • [Cites] Development. 1993 Apr;117(4):1183-98 [8404525.001]
  • [Cites] Perspect Dev Neurobiol. 1994;2(1):111-16 [7530137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23 [7836085.001]
  • [Cites] Methods Enzymol. 1994;245:52-61 [7539094.001]
  • [Cites] Int Arch Allergy Immunol. 1995 Aug;107(4):484-90 [7620364.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):445-7 [8980244.001]
  • [Cites] Matrix Biol. 1998 Aug;17(4):305-16 [9749946.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):1035-41 [9816077.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1687-92 [9893653.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):415-21 [10366470.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • (PMID = 15735164.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1770604
  •  go-up   go-down


29. Swanger RS, Brudnicki A: Ultrasound of ovarian sex-cord tumor with annular tubules. Pediatr Radiol; 2007 Dec;37(12):1270-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound of ovarian sex-cord tumor with annular tubules.
  • The association of Peutz-Jeghers syndrome (PJS) with bilateral benign, typically multifocal, small, and sometimes calcified SCTAT has also been reported.
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1511-4 [3587280.001]
  • [Cites] Cancer. 1970 May;25(5):1107-21 [5429475.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jul;25(3):199-215 [16810055.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1384-402 [7104978.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):584-90 [12808064.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):466-70 [10786816.001]
  • (PMID = 17764009.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Gonçales ES, Rubira-Bullen IF, Rubira CM, Miyazawa M, Chinellato LE, Consolaro A: Eosinophilic ulcer of the oral mucosa versus squamous cell carcinoma. Quintessence Int; 2007 Sep;38(8):677-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eosinophilic ulcer of the oral mucosa is a benign, rare, self-limiting, and generally asymptomatic lesion that shows spontaneous regression.
  • Its etiopathogenesis is still uncertain, but trauma seems to play a fundamental role in the occurrence of this tumor.
  • In these cases, the differential diagnosis with squamous cell carcinoma is made.
  • A case of very small eosinophilic ulcer of the oral mucosa located on the lateral border of the tongue is presented.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


31. Ren Y, Wu L, Frost AR, Grizzle W, Cao X, Wan M: Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer. Mol Cancer; 2009 Nov 27;8:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: TGF-beta resistance often develops in breast cancer cells that in turn overproduce this cytokine to create a local immunosuppressive environment that fosters tumor growth and exacerbates the invasive and metastatic behavior of the tumor cells themselves.
  • METHODS: Effect of TGF-beta on ERalpha-mediated gene transcription was investigated in breast cancer cell lines using transient transfection, real-time PCR, sequential DNA precipitation, and small interfering RNA assays.
  • There appears a dynamic change of Smad4 expression from benign breast ductal tissue to infiltrating ductal carcinoma.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2008 Apr;32(4):791-6 [18360706.001]
  • [Cites] Breast Cancer Res. 2007;9(4):305 [17705882.001]
  • [Cites] Cell Oncol. 2008;30(4):337-47 [18607068.001]
  • [Cites] Cells Tissues Organs. 2008;188(1-2):225-35 [18303245.001]
  • [Cites] Hum Mutat. 2009 Feb;30(2):E451-9 [19058223.001]
  • [Cites] Breast Cancer Res. 2009;11(1):202 [19291273.001]
  • [Cites] Exp Mol Pathol. 2009 Aug;87(1):48-53 [19341727.001]
  • [Cites] Nat Cell Biol. 2001 Jun;3(6):587-95 [11389444.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42908-14 [11555647.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2635-42 [12072396.001]
  • [Cites] Cell. 2002 Jul 12;110(1):19-32 [12150994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15192-200 [12576474.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):799-804 [12821112.001]
  • [Cites] Development. 2003 Dec;130(24):6143-53 [14597578.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1643-57 [15056732.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):299-303 [2295070.001]
  • [Cites] Mol Cell Endocrinol. 1993 Nov;97(1-2):115-23 [8143893.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):513-29 [7844613.001]
  • [Cites] J Cell Biochem. 1996 Apr;61(1):9-17 [8726350.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7749-56 [9516484.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):98-103 [10077159.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4879-83 [10490821.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):937s-43s [15701890.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):372-83 [15645498.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R753-64 [16168121.001]
  • [Cites] JAMA. 2005 Oct 5;294(13):1634-46 [16204663.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:659-93 [16212511.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3044-50 [16540653.001]
  • [Cites] BMC Cancer. 2006;6:25 [16438724.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):601-7 [16627986.001]
  • [Cites] Hum Mutat. 2006 Sep;27(9):897-905 [16865698.001]
  • [Cites] Cell Biochem Biophys. 2006;46(1):79-90 [16943625.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2148-56 [16698802.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):433-42 [17167985.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:119-26 [17261761.001]
  • [Cites] J Pathol. 2007 Apr;211(5):499-506 [17236182.001]
  • [Cites] Nat Genet. 2007 May;39(5):655-60 [17417639.001]
  • [Cites] Front Biosci. 2007;12:4393-401 [17485383.001]
  • [Cites] Exp Mol Pathol. 2007 Jun;82(3):284-91 [17289018.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):905-31 [17615392.001]
  • [Cites] Prostate. 2008 May 1;68(6):661-74 [18213629.001]
  • (PMID = 19943940.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK60913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2787496
  •  go-up   go-down


32. Sepe PS, Brugge WR: A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol; 2009 Jun;6(6):363-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A guide for the diagnosis and management of gastrointestinal stromal cell tumors.
  • Gastrointestinal stromal cell tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract and are frequently detected on routine endoscopy.
  • Preoperative determination of malignancy risk can be estimated from tumor size and location, but reliable histopathologic criteria are not currently available.
  • Given such biological uncertainty, accurate diagnosis is essential to differentiate these lesions from other truly benign, subepithelial tumors.
  • Endoscopic ultrasound-guided fine-needle aspiration has emerged as an important procedure to secure a tissue diagnosis of a GIST.
  • When encountering GISTs, gastroenterologists are faced with challenging management decisions, especially in the face of small, incidentally discovered lesions.
  • This Review provides a general overview of GISTs, with an emphasis on their endoscopic diagnosis, the management of localized disease, and the management of incidentally discovered GISTs.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / surgery. Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / surgery. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365407.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


33. Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, Sauter G, Haese A: Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol; 2010 Dec;28(6):687-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Angiogenesis is an important part in tumor progression and intratumoral microvessel density (MVD) has proven a prognostic factor in several solid tumors.
  • However, its value in prostate cancer is still unclear, especially in small biopsy samples.
  • RESULTS: MVD was higher in TMA spots containing cancer as compared to benign tissue (P < 0.001).
  • Furthermore, a higher MVD correlated with tumor location in the peripheral zone (P = 0.01).
  • CONCLUSIONS: MVD in prostate cancer is closely related to other factors contributing to tumor aggressiveness.
  • [MeSH-major] Disease Progression. Microvessels / pathology. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / blood supply. Prostatic Neoplasms / diagnosis


34. Poomsawat S, Punyasingh J: Calcifying epithelial odontogenic tumor: an immunohistochemical case study. J Mol Histol; 2007 Mar;38(1):103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumor: an immunohistochemical case study.
  • Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic tumor.
  • Globules of amyloid-like material among the tumor cells were prominent.
  • Also found was a small area demonstrating a cribriform pattern.
  • Tumor cells expressed laminins 1 and 5, fibronectin, cytokeratins and vimentin.
  • A number of dendritic cells among sheets of tumor cells were revealed with strong staining for S-100 protein and CD 1a.
  • [MeSH-major] Mandibular Neoplasms / metabolism. Mandibular Neoplasms / pathology. Neoplasm Proteins / metabolism. Odontogenic Cyst, Calcifying / metabolism. Odontogenic Cyst, Calcifying / pathology

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 1993 Sep;22(8):378-83 [8283404.001]
  • [Cites] J Oral Pathol. 1985 Feb;14(2):133-40 [2580070.001]
  • [Cites] Oral Dis. 2001 May;7(3):171-6 [11495193.001]
  • [Cites] Biotech Histochem. 1995 May;70(3):114-8 [7548432.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Nov;104(5):666-75 [17150384.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Sep;63(9):1377-82 [16122606.001]
  • [Cites] J Lab Clin Med. 2003 Nov;142(5):348-55 [14647039.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Mar;95(3):332-9 [12627106.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):e12-5 [16997086.001]
  • [Cites] Hum Pathol. 1983 Feb;14(2):108-26 [6339357.001]
  • [Cites] J Oral Pathol Med. 1990 Oct;19(9):430-4 [2269939.001]
  • [Cites] J Oral Pathol Med. 1992 Mar;21(3):113-9 [1374797.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):17-26 [10889914.001]
  • [Cites] J Oral Pathol. 1981 Dec;10(6):417-29 [6174718.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):501-5 [3539313.001]
  • [Cites] J Oral Pathol Med. 1991 Feb;20(2):93-5 [2016701.001]
  • [Cites] J Oral Pathol. 1982;11(5):399-406 [6815318.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):287-95 [11925538.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):852-5 [15944987.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Sep;63(9):1361-8 [16122602.001]
  • [Cites] J Oral Pathol Med. 1999 Apr;28(4):187-91 [10235374.001]
  • [Cites] Int Dent J. 2004 Dec;54(6):457-60 [15633503.001]
  • [Cites] J Oral Pathol. 1988 May;17(5):236-40 [2462621.001]
  • [Cites] J Oral Pathol. 1983 Oct;12(5):366-74 [6415257.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):872-6 [10835524.001]
  • [Cites] Connect Tissue Res. 1995;32(1-4):9-15 [7554939.001]
  • [Cites] Oral Dis. 2003 Jan;9(1):1-6 [12617250.001]
  • (PMID = 17318341.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


35. Balke M, Streitbuerger A, Budny T, Henrichs M, Gosheger G, Hardes J: Treatment and outcome of giant cell tumors of the pelvis. Acta Orthop; 2009 Oct;80(5):590-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 20 patients with histologically benign GCT of the pelvis were included in this study.
  • RESULTS: 1 patient with a pubic tumor developed a local recurrence 1 year after intralesional resection and additional curettage of the margins.
  • The recurrence presented as a small soft tissue mass within the scar tissue of the gluteal muscles and was treated by resection.
  • [MeSH-major] Bone Neoplasms / surgery. Giant Cell Tumor of Bone / surgery. Pelvic Bones
  • [MeSH-minor] Adult. Aged. Bone Cements. Bone Transplantation. Curettage. Embolization, Therapeutic / methods. Female. Follow-Up Studies. Humans. Ilium / pathology. Ilium / surgery. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop. 2008 Feb;79(1):86-93 [18283578.001]
  • [Cites] Spine (Phila Pa 1976). 2007 May 1;32(10):1107-15 [17471094.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Jan;135(1):149-58 [18521629.001]
  • [Cites] J Surg Oncol. 2009 Mar 1;99(3):169-72 [19072993.001]
  • [Cites] J Bone Joint Surg Am. 1999 Nov;81(11):1566-73 [10565648.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1317-25 [12216101.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jun;(423):196-207 [15232449.001]
  • [Cites] Clin Orthop Relat Res. 1969 Jan-Feb;62:187-91 [5774834.001]
  • [Cites] J Bone Joint Surg Am. 1978 Sep;60(6):731-46 [701308.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] Acta Orthop Scand. 1984 Apr;55(2):209-14 [6369866.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Clin Orthop Relat Res. 1987 Sep;(222):123-31 [3621712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1085-8 [2808042.001]
  • [Cites] Chir Organi Mov. 1991 Oct-Dec;76(4):311-6 [1800042.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):29-36 [1563165.001]
  • [Cites] J Bone Joint Surg Am. 1993 Oct;75(10):1466-75 [8408135.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):495-8 [16896875.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Sep;134(9):969-78 [18322700.001]
  • (PMID = 19916695.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2823344
  •  go-up   go-down


36. Lee D, Suh YL, Han J, Kim ES: Spinal nerve sheath myxoma (neurothekeoma). Pathol Int; 2006 Mar;56(3):144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nerve sheath myxoma (NSM) is a rare, benign tumor of predominantly cutaneous location.
  • They usually arise from small cutaneous nerves in the head, neck, and extremities, but exceptionally they arise from spinal nerve roots.
  • Spine magnetic resonance imaging showed small intradural extramedullary masses at the L2-3 level.
  • Ultrastructural observation of tumor cells with perineurial, fibroblast-like, and Schwann-cell differentiation suggests an origin from nerve sheath precursor cells.
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497247.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


37. Yang TM, Leu SW, Li JM, Hung MS, Lin CH, Lin YC, Huang TJ, Tsai YH, Yang CT: WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. J Cancer Res Clin Oncol; 2009 Jul;135(7):919-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
  • PURPOSE: Malignant pleural effusion is an important staging criterion in non-small cell lung cancer (NSCLC).
  • METHODS: We performed WIF-1 promoter region MSP in 36 definite malignant pleural effusions from consecutive NSCLC patients and 35 pleural effusion specimens of benign origin.
  • In addition, the results of WIF-1 promoter region MSP were negative in all 35 patients with pleural effusion of benign origin.
  • CONCLUSIONS: WIF-1 promoter region MSP might be used as an adjuvant tool to complement cytologic examination for the diagnosis of NSCLC-related malignant pleural effusion.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. DNA Methylation. Lung Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Promoter Regions, Genetic. Repressor Proteins / genetics
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Thorax. 2008 Jan;63(1):35-41 [17573438.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii8-17 [12728146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23 [14973184.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):517-24 [16237222.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):47-50 [9815536.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Eur Respir J. 2003 Sep;22(3):422-6 [14516130.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 10;341(2):635-40 [16427602.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1761-6 [16708382.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6598-605 [12242657.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2191-5 [17285579.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):1241-7 [16181847.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1180-8; discussion 1180-8 [15797047.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6087-92 [17947472.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):413-5 [15913841.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):895-904 [18308762.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):1-9 [16893591.001]
  • (PMID = 19085002.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Repressor Proteins; 0 / WIF1 protein, human
  •  go-up   go-down


38. Fei JW, de Villiers EM: Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation. Int J Cancer; 2008 Jul 1;123(1):108-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanism by which the E6 protein of cutaneous HPV types interacts with cellular proteins to induce either benign or malignant cutaneous lesions, has not been elucidated, although extensive ultraviolet exposure and mutated p53 (hot-spot mutations) are known to be associated with non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / virology. Caspase 3 / metabolism. DNA-Binding Proteins / metabolism. Lung Neoplasms / virology. Mutation. Oncogene Proteins, Viral / metabolism. Trans-Activators / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Apoptosis. Arginine. Blotting, Western. Cell Line, Tumor. Glutathione Transferase / metabolism. Humans. Immunoprecipitation. Mass Spectrometry. Papillomavirus Infections / metabolism. Transcription Factors. Tryptophan. Tumor Virus Infections / metabolism. Ubiquitin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18412244.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / E6 protein, human papillomavirus type 20; 0 / Oncogene Proteins, Viral; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Ubiquitin; 0 / Vimentin; 8DUH1N11BX / Tryptophan; 94ZLA3W45F / Arginine; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


39. Kashiwagi S, Kumasaka T, Bunsei N, Fukumura Y, Yamasaki S, Abe K, Mitani K, Abe H, Matsumoto T, Suda K: Detection of Epstein-Barr virus-encoded small RNA-expressed myofibroblasts and IgG4-producing plasma cells in sclerosing angiomatoid nodular transformation of the spleen. Virchows Arch; 2008 Sep;453(3):275-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Epstein-Barr virus-encoded small RNA-expressed myofibroblasts and IgG4-producing plasma cells in sclerosing angiomatoid nodular transformation of the spleen.
  • Sclerosing angiomatoid nodular transformation (SANT) of the spleen is a rare inflammatory tumor-like lesion composed of vascular nodules and non-neoplastic stroma including spindle cells and inflammatory cells.
  • In one case, 20-30% of the myofibroblasts in Epstein-Barr-virus (EBV)-positive spindle cells were detected using double-labeling immunohistochemistry for alpha-SMA and EBV-encoded small RNA in situ hybridization.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epstein-Barr Virus Infections / immunology. Epstein-Barr Virus Infections / pathology. Female. Fibroblasts / immunology. Fibroblasts / pathology. Granuloma, Plasma Cell / diagnosis. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / immunology. Humans. Immunoglobulin G / genetics. Immunohistochemistry. Male. Middle Aged. Myoblasts / immunology. Myoblasts / pathology. Plasma Cells / metabolism. Plasma Cells / virology. RNA, Viral / metabolism. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Jul;41(7):613-25 [16932997.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):124-31 [14720144.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1538-46 [17518371.001]
  • [Cites] Eur J Haematol. 2004 Apr;72(4):285-91 [15089768.001]
  • [Cites] Virchows Arch. 2007 Jul;451(1):73-9 [17492312.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):56-61 [12866373.001]
  • [Cites] Hum Pathol. 2001 Dec;32(12):1382-7 [11774173.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1268-79 [15371942.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):354-60 [11301353.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):57-60 [15029264.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1807-16 [17525249.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):155-60 [9606806.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):931-8 [12218210.001]
  • [Cites] J Gastroenterol. 2000;35(7):563-6 [10905367.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):379-85 [11231487.001]
  • [Cites] J Pathol. 2008 Jan;214(2):199-210 [18161745.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):280-9 [16785523.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Gut. 2003 May;52(5):683-7 [12692053.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1093-8 [7557942.001]
  • (PMID = 18696108.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / RNA, Viral
  •  go-up   go-down


40. Gill RK, Vazquez MF, Kramer A, Hames M, Zhang L, Heselmeyer-Haddad K, Ried T, Shilo K, Henschke C, Yankelevitz D, Jen J: The use of genetic markers to identify lung cancer in fine needle aspiration samples. Clin Cancer Res; 2008 Nov 15;14(22):7481-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We selected regions of frequent copy number gains in chromosomes 1q32, 3q26, 5p15, and 8q24 in non-small cell lung cancer and tested their ability to determine the neoplastic state of cells obtained by FNA using fluorescent in situ hybridization.
  • RESULTS: Nontumor lung tissues had < or= 4 signals per nucleus for all tested markers, whereas tumor samples had > or = 5 signals per nucleus in five or more cells for at least one marker.
  • Genetic analysis identified 15 cases as tumor and 21 cases as nontumor.
  • Clinical and pathologic diagnoses confirmed the genetic test in 15 of 16 lung cancer cases regardless of tumor subtype, stage, or size and in 20 of 20 cases diagnosed as benign lung diseases.
  • CONCLUSIONS: A set of only four genetic markers can distinguish the neoplastic state of lung lesion using small samples obtained through computed tomography-guided FNA.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biopsy, Needle. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Interv Radiol. 2004 Feb;15(2 Pt 1):161-4 [14963182.001]
  • [Cites] Ann Intern Med. 2004 May 4;140(9):740-53 [15126259.001]
  • [Cites] Chest. 2004 Sep;126(3):761-5 [15364754.001]
  • [Cites] Lab Invest. 1989 Aug;61(2):235-42 [2755080.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):644-51 [1985781.001]
  • [Cites] Diagn Cytopathol. 1990;6(5):317-22 [2292218.001]
  • [Cites] Cytometry. 1991;12(7):614-21 [1723676.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):307-17 [7678720.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1801-6 [8137295.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):781-5 [8206672.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5030-7 [7585547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):479-84 [8552665.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Jun;16(2):106-12 [8818657.001]
  • [Cites] Chest. 1997 Jun;111(6):1691-6 [9187195.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2331-5 [9192802.001]
  • [Cites] Clin Imaging. 1998 Jan-Feb;22(1):7-10 [9421648.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):79-82 [9591638.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7820-6 [15585613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1968-73 [10766187.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):689 [10934171.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):87-99 [11369051.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):282-7 [11391799.001]
  • [Cites] Cancer. 2001 Dec 25;93(6):364-75 [11748576.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1861-7 [11789761.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13 [11850344.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6877-83 [12362270.001]
  • [Cites] Cancer. 2002 Oct 25;96(5):306-15 [12378599.001]
  • [Cites] Radiology. 2003 Mar;226(3):756-61 [12601181.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):103-12 [12707375.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):369-76 [12923544.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1405-16 [14507648.001]
  • [Cites] Chest. 2005 Aug;128(2):906-11 [16100185.001]
  • [Cites] Radiology. 2006 May;239(2):586-90 [16641357.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):331-8 [16847471.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):252-8 [17614298.001]
  • (PMID = 19010865.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010163-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS74285; NLM/ PMC2586966
  •  go-up   go-down


41. Alves CA, Ribeiro Júnior O, Borba AM, Gouveia MM, Guimarães Júnior J, Aburad A, de Souza SC: Pleomorphic multicentric adenoma in the submandibular gland. Head Neck Pathol; 2007 Dec;1(2):178-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplasms of salivary glands represent a small group among the diseases involving the head and neck complex.
  • In this group, the pleomorphic adenoma is the most frequent neoplasm, yet involves the submandibular gland in only 12.3% of cases.
  • This multicentric finding is of great interest, perhaps explaining the recurrence rate of this neoplasm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Dec;128(12):1400-3 [12479728.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Jul;68(7):895-902 [15183580.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Oct;62(10):1203-8 [15452806.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1219-24 [2917323.001]
  • [Cites] J Oral Maxillofac Surg. 1995 May;53(5):506-8; discussion 509 [7722716.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):3-7 [8729611.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Dec;34(6):515-9 [8971446.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Sep;55(9):1011-4 [9294517.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):533-6 [16053874.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Jul;35(7):608-12 [16540285.001]
  • (PMID = 20614272.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2807518
  • [Keywords] NOTNLM ; Benign neoplasm / Multicentric tumor / Pleomorphic adenoma / Salivary gland tumor / Submandibular gland
  •  go-up   go-down


42. Bonkhoff H, Fixemer T: [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype]. Pathologe; 2005 Nov;26(6):453-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neuroendokrine Differenzierung im Prostatakarzinom. Ein Marker für die Androgen- und Strahlenresistenz.
  • Neuroendocrine (NE) differentiation frequently occurs in common prostatic malignancies but usually escapes pathological and clinical detection.
  • The present review focuses on biological properties of NE tumor cells making them resistant to androgen deprivation and radiation therapy.
  • Recent data have shown that NE prostate cancer cells (as defined by the most commonly used endocrine marker chromogranin A) are arrested in the G0-phase of the cell cycle and do not undergo apoptosis.
  • This particular phenotype consistently lacks the nuclear androgen receptor in both benign and malignant conditions but produces a series of hormonal growth factors exerting mitogenic stimuli on adjacent, exocrine tumor cells.
  • Neoplastic NE cells devoid of the nuclear androgen receptor constitute an androgen-insensitive cell population in prostate cancer.
  • The absence of proliferative and apoptotic activity makes NE tumor cells particularly resistant towards cytotoxic drugs and radiation therapy.
  • Pathological and clinical detection of NE features is recommended for all prostate cancer patients for whom radiation therapy and androgen deprivation is being considered.
  • [MeSH-minor] Adenocarcinoma / pathology. Apoptosis / physiology. Carcinoid Tumor / pathology. Carcinoma, Small Cell / pathology. Cell Division / physiology. Diagnosis, Differential. Growth Substances / analysis. Humans. Male. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / radiotherapy. Prognosis. Prostate / pathology. Prostate / radiation effects. Receptors, Androgen / analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2003 Mar;91(5):438-45 [12603395.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2525-9 [12174956.001]
  • [Cites] Hum Pathol. 1996 Jul;27(7):683-7 [8698312.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):995-1000 [10888774.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1363-6 [11396214.001]
  • [Cites] Prostate. 1996 Feb;28(2):98-106 [8604398.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):126-33 [11170140.001]
  • [Cites] Prostate. 1994;24(3):114-8 [7509483.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):167-70 [7532147.001]
  • [Cites] Prostate. 2003 May 15;55(3):168-79 [12692782.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):195-202 [9769121.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):71-3 [10071238.001]
  • [Cites] Prostate. 2004 Mar 1;58(4):421-8 [14968443.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(4):291-4 [7694424.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1475-9 [11396235.001]
  • [Cites] J Formos Med Assoc. 2003 Jul;102(7):480-5 [14517586.001]
  • [Cites] Eur Urol. 2003 Aug;44(2):215-21 [12875941.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):357-61 [8674017.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):1-9 [9422516.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6C):5663-6 [10697637.001]
  • [Cites] Hum Pathol. 1994 Jan;25(1):42-6 [7508883.001]
  • [Cites] Prostate Suppl. 1998;8:18-22 [9690659.001]
  • [Cites] Cancer. 1997 Dec 1;80(11):2109-19 [9392333.001]
  • [Cites] J Urol. 2003 Nov;170(5):1812-6 [14532782.001]
  • [Cites] Prostate. 1991;19(2):91-8 [1717965.001]
  • [Cites] Prostate. 1996 Oct;29(4):261-7 [8876709.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2590-7 [10861438.001]
  • (PMID = 16195860.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Receptors, Androgen
  •  go-up   go-down


43. Korzeniewski N, Wheeler S, Chatterjee P, Duensing A, Duensing S: A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention. Mol Cancer; 2010 Jun 17;9:153
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore test here whether small molecule CDK inhibitors derived from the bis-indole indirubin can be used to suppress centrosome aberrations as a novel approach to chemoprevention of malignant progression.
  • Remarkably, a considerable proportion (72.7%) of benign mammary tissue samples scored also positive for nuclear AhR overexpression.
  • We furthermore provide evidence that continued expression of endogenous AhR is critical to promote centriole overduplication induced by cyclin E and that AhR and cyclin E may function in the same pathway.
  • Future studies are warranted to determine whether individuals in which nuclear AhR overexpression is detected in benign mammary tissue are at a higher risk for developing pre-cancerous or cancerous breast lesions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Mol Mutagen. 2009 Oct;50(8):649-53 [19274767.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] PLoS One. 2010;5(2):e9060 [20140206.001]
  • [Cites] Nat Cell Biol. 1999 May;1(1):60-7 [10559866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9990-5 [12107286.001]
  • [Cites] Mol Pharmacol. 2003 Jun;63(6):1373-81 [12761348.001]
  • [Cites] Mutat Res. 2003 Sep 9;540(1):99-105 [12972062.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):346-52 [14506732.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1930-8 [14755252.001]
  • [Cites] Oncogene. 2004 May 27;23(25):4400-12 [15077192.001]
  • [Cites] Oncogene. 2004 Oct 28;23(50):8206-15 [15378001.001]
  • [Cites] Cell. 1992 Sep 18;70(6):993-1006 [1388095.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):297-300 [10499591.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):263-74 [15557799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18123-8 [15601761.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):352-9 [15890539.001]
  • [Cites] J Cell Biochem. 2005 Dec 15;96(6):1174-84 [16211578.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1140-6 [16244668.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2943-9 [16331279.001]
  • [Cites] Biol Chem. 2006 Sep;387(9):1175-87 [16972784.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2717-23 [17016823.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):215-23 [16819507.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):499-500 [17392771.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):562-6 [17392787.001]
  • [Cites] J Cell Sci. 2007 Jul 1;120(Pt 13):2139-42 [17591686.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6280-8 [17438528.001]
  • [Cites] Adv Exp Med Biol. 2007;608:52-69 [17993232.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):911-24 [18004399.001]
  • [Cites] Virology. 2008 Mar 1;372(1):157-64 [18036631.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1657-64 [17891176.001]
  • [Cites] J Cell Biochem. 2008 May 15;104(2):402-17 [18059014.001]
  • [Cites] Adv Exp Med Biol. 2005;570:393-421 [18727509.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1877-84 [19223546.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jun;115(3):651-9 [19107593.001]
  • [Cites] Nature. 2009 Jul 9;460(7252):278-82 [19506557.001]
  • [Cites] Cancer Res. 2009 Aug 15;69(16):6668-75 [19679553.001]
  • [Cites] Endocr Relat Cancer. 2009 Sep;16(3):835-44 [19447902.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1941-51 [10595924.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2943-50 [10644764.001]
  • [Cites] J Cell Biol. 2000 Apr 17;149(2):317-30 [10769025.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(2):117-31 [11097088.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5498-506 [11114727.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2356-60 [11289095.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31475-8 [11425848.001]
  • [Cites] Environ Mol Mutagen. 2009 Oct;50(8):741-7 [19326465.001]
  • (PMID = 20565777.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112598
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Receptors, Aryl Hydrocarbon
  • [Other-IDs] NLM/ PMC2898706
  •  go-up   go-down


44. Krampulz T, Hans VH, Oppel F, Dietrich U, Puchner MJ: Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report. J Neurooncol; 2006 May;77(3):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term relapse-free survival with supratentorial primitive neuroectodermal tumor in an adult: a case report.
  • OBJECTIVE: In adults, supratentorial primitive neuroectodermal tumor (sPNET) is a very rare undifferentiated embryoblastic neoplasm.
  • CT- and MRI-scans revealed a right occipital tumor with moderate contrast enhancement.
  • The tumor was completely removed.
  • The original histological diagnosis was that of an undifferentiated sarcoma, malignant hemangioendothelioma, grade III.
  • Admission for another reason in 2003 led to a re-evaluation of the original diagnosis.
  • Microscopy revealed a malignant, highly cellular, poorly differentiated tumor with a desmoplastic component.
  • Up to 20% of tumor nuclei were labeled for Ki-67.
  • According to these findings, the diagnosis was changed to a sPNET (WHO IVdegrees ).
  • Other tumor entities were excluded by immunohistochemistry.
  • CONCLUSIONS: Although the prognosis of sPNET is reported to be poor, a small fraction with a rather benign biological and clinical behavior exists.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neuroectodermal Tumors, Primitive / pathology. Sarcoma / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Humans. Ki-67 Antigen / metabolism. Male. Receptor, Nerve Growth Factor / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jan;41(1):56-63 [626943.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):62-5 [12595327.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):840-4 [7260835.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1027-35 [10694553.001]
  • [Cites] Pediatr Neurosurg. 1998 Oct;29(4):170-7 [9876245.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):268-73 [11452934.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):77-80 [2170592.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Acta Oncol. 2003;42(1):55-61 [12665332.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):57-62 [11451203.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):142-8 [10391574.001]
  • [Cites] Surg Neurol. 1983 Jul;20(1):30-5 [6306852.001]
  • [Cites] Ann Neurol. 1996 Apr;39(4):481-9 [8619526.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):113-20 [12622449.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):905-9 [2033450.001]
  • [Cites] Br J Neurosurg. 1999 Feb;13(1):90-2 [10492697.001]
  • [Cites] Acta Cytol. 2000 Nov-Dec;44(6):1050-8 [11127734.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Jan;42(1):1-15 [6296325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):951-7 [7607969.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):43-52 [12416545.001]
  • [Cites] J Neurooncol. 1998 Feb;36(3):259-67 [9524104.001]
  • [Cites] BMC Cancer. 2004 Jan 26;4:3 [14969593.001]
  • (PMID = 16528456.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptor, Nerve Growth Factor
  •  go-up   go-down


46. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y: The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol; 2009 Feb;131(2):264-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid neoplasia.
  • LMO2 is uniformly expressed in benign vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone.
  • Among nonvascular neoplasms, LMO2 reactivity is present in giant cell tumor of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141387.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / CA122105; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / P30 CA124435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS636776; NLM/ PMC4305438
  •  go-up   go-down


47. Arndt S, Bosserhoff AK: TANGO is a tumor suppressor of malignant melanoma. Int J Cancer; 2006 Dec 15;119(12):2812-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TANGO is a tumor suppressor of malignant melanoma.
  • In our study we revealed that TANGO was downregulated or lost in 9 melanoma cell lines when compared to normal melanocytes and in most of the 8 tumor samples analyzed.
  • A small reduction of TANGO was also seen in different benign and atypical nevi when compared to normal skin.
  • Our studies, therefore, indicate that reduction of TANGO expression contributes to tumor progression.
  • These results taken together provide the first indications for a tumor suppressor role of TANGO gene in human malignant melanoma.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Movement. Cell Proliferation. DNA, Antisense / genetics. Gene Expression Regulation, Neoplastic. Humans. Plasmids / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic / genetics. Transfection. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17044017.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / DNA, Antisense; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  •  go-up   go-down


48. Bhattacharjee N, Li N, Keenan TM, Folch A: A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors. Integr Biol (Camb); 2010 Nov;2(11-12):669-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors.
  • The most widely used experimental paradigms that elicit axon guidance in vitro utilize as the source of the gradient a pulsatile pipette, transfected cells, or a loaded gel, producing time-varying gradients of poor reproducibility which are not well suited for studying slow-growing mammalian cells.
  • In this paper, we describe axonal responses of mouse cortical neurons in a "neuron-benign" gradient-generator device based on an open chamber that can establish highly stable gradients of diffusible molecules for at least 6 h with negligible shear stress, and also allows the neurons to thrive for at least 2 weeks.
  • The gradient stability and uniformity over the cell culture surface achieved by the device, together with our software platform for acquiring, post-processing and quantitatively analyzing the large number of images allowed us to extract valuable information even from small datasets.
  • [MeSH-minor] Animals. Axons / drug effects. Axons / physiology. Cell Culture Techniques. Cell Tracking. Equipment Design. Female. Mice. Nerve Growth Factors / pharmacology. Neurogenesis. Pregnancy. Signal Transduction. Tumor Suppressor Proteins / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 1996 Aug;17(2):203-15 [8780645.001]
  • [Cites] J Neurosci Res. 1995 Dec;42(5):674-83 [8600300.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Mol Cell Neurosci. 1997;8(6):417-29 [9143559.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):275-9 [9230436.001]
  • [Cites] Neuron. 1997 Sep;19(3):575-89 [9331350.001]
  • [Cites] Neuron. 1997 Dec;19(6):1211-24 [9427245.001]
  • [Cites] Development. 1997 Dec;124(24):5063-74 [9362464.001]
  • [Cites] Cell. 1999 Jun 25;97(7):821-4 [10399909.001]
  • [Cites] Curr Opin Neurobiol. 1999 Oct;9(5):603-15 [10508749.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):833-9 [15679351.001]
  • [Cites] Lab Chip. 2005 Apr;5(4):401-6 [15791337.001]
  • [Cites] Lab Chip. 2005 Jun;5(6):611-8 [15915253.001]
  • [Cites] Exp Cell Res. 2005 Dec 10;311(2):307-16 [16263111.001]
  • [Cites] Nat Neurosci. 2006 Apr;9(4):511-8 [16520734.001]
  • [Cites] Dev Biol. 2006 Apr 1;292(1):13-24 [16476423.001]
  • [Cites] Biomed Microdevices. 2006 Jun;8(2):109-18 [16688570.001]
  • [Cites] Development. 2006 Jul;133(13):2487-95 [16763203.001]
  • [Cites] Lab Chip. 2007 Jun;7(6):763-9 [17538719.001]
  • [Cites] Langmuir. 2007 Oct 23;23(22):10910-2 [17910490.001]
  • [Cites] Lab Chip. 2008 Jan;8(1):34-57 [18094760.001]
  • [Cites] Lab Chip. 2008 Feb;8(2):227-37 [18231660.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):698-706 [18469807.001]
  • [Cites] Lab Chip. 2008 Aug;8(8):1292-9 [18651071.001]
  • [Cites] Lab Chip. 2008 Sep;8(9):1468-77 [18818801.001]
  • [Cites] Lab Chip. 2008 Sep;8(9):1507-15 [18818806.001]
  • [Cites] Lab Chip. 2010 Jan 7;10(1):116-22 [20024059.001]
  • [Cites] Cell. 2010 May 14;141(4):632-44 [20434207.001]
  • [Cites] J Comp Neurol. 2000 Jan 10;416(2):201-12 [10581466.001]
  • [Cites] Int J Dev Neurosci. 2000 Nov;18(7):643-51 [10978842.001]
  • [Cites] Nat Neurosci. 2001 Nov;4 Suppl:1169-76 [11687826.001]
  • [Cites] Neuron. 2001 Nov 20;32(4):605-17 [11719202.001]
  • [Cites] Prog Neurobiol. 2001 Dec;65(6):593-608 [11728645.001]
  • [Cites] J Neurobiol. 2002 Apr;51(1):9-23 [11920724.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]
  • [Cites] Nat Biotechnol. 2002 Aug;20(8):826-30 [12091913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12542-7 [12237407.001]
  • [Cites] Lab Chip. 2004 Oct;4(5):420-4 [15472724.001]
  • [Cites] Nature. 1988 Dec 22-29;336(6201):775-8 [3205306.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • (PMID = 20957287.001).
  • [ISSN] 1757-9708
  • [Journal-full-title] Integrative biology : quantitative biosciences from nano to macro
  • [ISO-abbreviation] Integr Biol (Camb)
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064387
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1
  • [Other-IDs] NLM/ NIHMS513943; NLM/ PMC3786697
  •  go-up   go-down


49. Park YK, Kim EJ, Kim SW: Osteoblastoma of the ethmoid sinus. Skeletal Radiol; 2007 May;36(5):463-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An osteoblastoma is a benign bone tumor that most often occurs in the vertebral column and the long bones of the extremities.
  • Histologically, the lesion was composed of proliferating osteoblasts along with small trabeculae of woven bone and rich vascular fibrous stroma.
  • [MeSH-major] Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Osteoblastoma / diagnosis. Osteoblastoma / surgery. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1979 Oct;105(10 ):623-5 [485933.001]
  • [Cites] An Esp Pediatr. 1997 Jan;46(1):83-4 [9082899.001]
  • [Cites] J Clin Pathol. 1993 Nov;46(11):1024-9 [8254089.001]
  • [Cites] Ann Laringol Otol Rinol Faringol. 1965;64(6):768-77 [5218396.001]
  • [Cites] J Comput Tomogr. 1985 Oct;9(4):347-50 [4053663.001]
  • [Cites] Laryngorhinootologie. 1991 May;70(5):275-7 [2064707.001]
  • [Cites] Klin Oczna. 1975 Mar;45(3):247-51 [1117656.001]
  • [Cites] Otolaryngol Pol. 2004;58(3):649-52 [15311621.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1996 Dec 5;38(1):89-95 [9119598.001]
  • [Cites] Am J Clin Pathol. 1975 Mar;63(3):391-6 [1115044.001]
  • [Cites] Rhinology. 1983 Dec;21(4):373-5 [6665425.001]
  • [Cites] Cancer. 1974 May;33(5):1289-305 [4207295.001]
  • [Cites] Otolaryngol Pol. 1974;28(5):575-9 [4419075.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):625-8 [9322852.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):416-26 [3855268.001]
  • [Cites] Otolaryngol Head Neck Surg. 1980 Jul-Aug;88(4):397-402 [6821422.001]
  • [Cites] J Laryngol Otol. 1993 Aug;107(8):737-9 [8409731.001]
  • [Cites] Skeletal Radiol. 2002 Mar;31(3):179-82 [11935205.001]
  • [Cites] J Laryngol Otol. 1978 Apr;92(4):337-45 [641417.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):117-34 [8119712.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1976 Oct-Nov;93(10-11):661-8 [1027351.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;408(2-3):297-305 [3936268.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1343-4 [15868703.001]
  • [Cites] J Laryngol Otol. 1997 Sep;111(9):865-8 [9373556.001]
  • [Cites] Ann Pathol. 1985;5(2):131-6 [4041187.001]
  • [Cites] Head Neck Surg. 1983 Sep-Oct;6(1):605-9 [6629798.001]
  • [Cites] J Laryngol Otol. 1986 Feb;100(2):229-32 [3950490.001]
  • (PMID = 17265159.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Morana G, Guarise A: Cystic tumors of the pancreas. Cancer Imaging; 2006;6:60-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic tumors of the pancreas are less frequent than solid lesions and are often detected incidentally, as many of these lesions are small and asymptomatic.
  • Many lesions can cause a pancreatic cyst, most being non-neoplastic while approximately 10% are cystic tumors, ranging from benign to highly malignant tumors.
  • A presumptive diagnosis of pseudocyst based on imaging appearance alone can cause a diagnostic error, and neoplastic cysts of the pancreas are particularly susceptible to this misdiagnosis, which can result in inappropriate treatment.
  • According to the WHO classification, they can be subdivided on the basis of their histological type and biological behavior into benign tumors, borderline tumors, and malignant tumors.
  • Cystic pancreatic tumors can be subdivided into peripheral (serous cystadenomas, mucinous cystic tumors, solid and papillary epithelial neoplasms, cystic islet cell tumors), which do not communicate with the main pancreatic duct, and ductal tumors (mucinous tumor), according to their site of origin.
  • [MeSH-major] Cystadenoma / diagnosis. Diagnostic Imaging. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Radiographics. 1999 Nov-Dec;19(6):1447-63 [10555668.001]
  • [Cites] J Comput Assist Tomogr. 1999 Nov-Dec;23(6):906-12 [10589565.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):441-7 [10658722.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):7-15 [10721803.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Acta Radiol. 2000 Jul;41(4):343-7 [10937755.001]
  • [Cites] Ann Chir. 2000 Jul;125(6):571-7 [10986770.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):323-37; discussion 337-40 [11259696.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Dig Dis. 2001;19(1):57-62 [11385252.001]
  • [Cites] Eur Radiol. 2001;11(9):1626-30 [11511881.001]
  • [Cites] Eur Radiol. 2001;11(10):1939-51 [11702126.001]
  • [Cites] Abdom Imaging. 2001 Nov-Dec;26(6):640-7 [11907731.001]
  • [Cites] Radiology. 2002 May;223(2):547-53 [11997566.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Oct;12(4):673-96 [12607779.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(2):171-83 [7281507.001]
  • [Cites] Radiology. 1987 Oct;165(1):51-5 [3306789.001]
  • [Cites] Hepatogastroenterology. 1989 Dec;36(6):462-6 [2613167.001]
  • [Cites] Gastrointest Endosc. 1990 Jul-Aug;36(4):410-1 [2210291.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Gastrointest Radiol. 1991 Winter;16(1):53-61 [1991611.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):199-201 [1851710.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):465-71 [2065922.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):634-8 [1317671.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Am Surg. 1993 Nov;59(11):740-5 [7694532.001]
  • [Cites] Curr Probl Surg. 1994 Mar;31(3):165-243 [8168359.001]
  • [Cites] J Comput Assist Tomogr. 1994 May-Jun;18(3):420-6 [8188910.001]
  • [Cites] Radiology. 1996 Jun;199(3):707-11 [8637992.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):714-20 [8799419.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):967-70 [8884322.001]
  • [Cites] Am J Gastroenterol. 1996 Dec;91(12):2548-54 [8946984.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Int J Pancreatol. 1996 Oct;20(2):135-9 [8968870.001]
  • [Cites] Presse Med. 1996 Nov 23;25(36):1794-800 [8991029.001]
  • [Cites] J Comput Assist Tomogr. 1997 May-Jun;21(3):373-82 [9135643.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):887-90 [9149208.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):637-44; discussion 644-6 [9230804.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):433-49 [9536488.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Radiology. 1998 Jul;208(1):231-7 [9646818.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):554-8 [9734981.001]
  • [Cites] Scand J Gastroenterol. 1998 Aug;33(8):880-9 [9754738.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):467-70 [9931400.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1973-80 [9951850.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1981-5 [9951851.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):483-91 [10228848.001]
  • [Cites] Int J Pancreatol. 1999 Apr;25(2):123-33 [10360225.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jun;29(6):294-8 [10418558.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • (PMID = 16861136.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1693784
  •  go-up   go-down


51. Shaco-Levy R, Piura B: Uterine adenolipoleiomyoma: a tumor with potential of aggressive behavior. Int J Gynecol Pathol; 2008 Apr;27(2):252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenolipoleiomyoma: a tumor with potential of aggressive behavior.
  • Histology showed the mass to be composed of benign-appearing smooth muscle, mature adipose tissue, and bland endocervical-type glands.
  • The recurrent adenolipoleiomyoma contained, in addition, benign-appearing endometrial-type glands and stroma and showed small foci of atypically proliferating endocervical-type epithelium.
  • [MeSH-minor] Female. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317215.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Grieco MJ, Shantha Kumara HM, Baxter R, Dujovny N, Kalady MF, Cekic V, Luchtefeld M, Whelan RL: Minimally invasive colorectal resection is associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting. Surg Endosc; 2010 Oct;24(10):2617-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epidermal growth factor (EGF) stimulates tumor growth directly via tumor cell EGF receptors or indirectly via its proangiogenic effects.
  • This study's purpose was to determine the impact of minimally invasive colorectal resection (MICR) on postoperative (postop) plasma EGF levels in the colorectal cancer (CRC) and benign disease settings and to see if preoperative (PreOp) EGF levels are altered in cancer patients.
  • METHODS: MICR patients with benign pathology (n = 40) and CRC (n = 48) had blood samples taken PreOp and on postoperative days (POD) 1 and 3.
  • RESULTS: The cancer and benign groups were comparable except for age.
  • The mean PreOp CRC plasma EGF level (122.9 ± 75.9 pg/ml) was significantly higher than that of the benign group (85.3 ± 38.5 pg/ml) (p = 0.015).
  • The benign group's POD3 and POD7-14 EGF levels were significantly lower than the PreOp level; later levels returned toward baseline.
  • Small late sample size limited analysis.
  • MICR is associated with a significant decrease in EGF levels early postop in both cancer and benign settings.
  • Unlike the benign group, EGF blood levels in cancer patients remain low during the second postop month.
  • EGF may have value as a tumor marker.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2766-7; author reply 2768 [21416177.001]
  • [Cites] Cancer Res. 1974 Aug;34(8):2109-13 [4842257.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):283-7 [8631552.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5119-23 [3044581.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3823-30 [8706030.001]
  • [Cites] Gut. 1996 Apr;38(4):582-6 [8707092.001]
  • [Cites] Int J Cancer. 1990 Jun 15;45(6):1018-21 [2351482.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1293-6 [9137488.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):613-9 [9066588.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):162-5 [8391303.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):121-33 [7680247.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):353-62 [16474912.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] J Clin Invest. 1992 Oct;90(4):1352-60 [1401070.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):8-13 [1624295.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):186-94 [10638988.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • (PMID = 20354877.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


53. Puhaindran ME, Healey JH, Athanasian EA: Single ray amputation for tumors of the hand. Clin Orthop Relat Res; 2010 May;468(5):1390-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of this procedure in the management of aggressive benign or malignant hand tumors has been described only in case reports and small case series.
  • We retrospectively reviewed the records of all 25 patients who underwent single ray amputations at our center during a 10-year period; there were seven index, five middle, six ring, and seven small ray amputations performed.
  • The other was treated with radiotherapy alone, as local tumor control would have required a hand amputation.
  • Functional assessment based on the Musculoskeletal Tumor Society staging system showed an average of 27.5 (range, 21-30).
  • However, function can be compromised by radiotherapy and a decrease in grip strength by a mean of 34% is to be expected.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hand Surg Br. 2005 Oct;30(5):504-6 [15992973.001]
  • [Cites] J Pediatr Surg. 1997 May;32(5):698-702 [9165454.001]
  • [Cites] Arch Orthop Trauma Surg. 2008 Oct;128(10):1017-21 [17876592.001]
  • [Cites] J Hand Surg Eur Vol. 2009 Feb;34(1):35-9 [19091738.001]
  • [Cites] Clin Orthop. 1959;15:35-59 [13831694.001]
  • [Cites] J Hand Surg Am. 1999 Nov;24(6):1245-8 [10584948.001]
  • [Cites] Plast Reconstr Surg. 2001 Sep 15;108(4):885-96 [11547143.001]
  • [Cites] Plast Reconstr Surg. 2003 Apr 1;111(4):1573-4 [12618628.001]
  • [Cites] Hand Surg. 2003 Jul;8(1):47-51 [12923934.001]
  • [Cites] J Hand Surg Br. 2003 Dec;28(6):578-81 [14599832.001]
  • [Cites] J Hand Surg Br. 2003 Dec;28(6):602-8 [14599838.001]
  • [Cites] J Bone Joint Surg Am. 1986 Jun;68(5):743-6 [3459730.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2482-91 [2249188.001]
  • [Cites] J Hand Surg Am. 1990 Nov;15(6):980-6 [2269796.001]
  • [Cites] Orthop Rev. 1992 Aug;21(8):983-4, 990-5 [1523013.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Hand Surg Am. 1993 Mar;18(2):271-7 [8463593.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):735-45 [8040019.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):473-8 [8636760.001]
  • [Cites] J Hand Surg Am. 1997 Jan;22(1):91-8 [9018620.001]
  • [Cites] J Hand Surg Eur Vol. 2007 Aug;32(4):460-1 [17950200.001]
  • (PMID = 19655212.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2853661
  •  go-up   go-down


54. Raymond MN, Robin P, De Zen F, Vilain G, Tanfin Z: Differential endothelin receptor expression and function in rat myometrial cells and leiomyoma ELT3 cells. Endocrinology; 2009 Oct;150(10):4766-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine leiomyoma are the most common benign tumors of the myometrium.
  • We previously identified endothelin (ET)-1 as a proliferative and antiapoptotic factor in Eker rat-derived leiomyoma (ELT3) cells.
  • Here we investigated, in ELT3 and myometrial cells, the respective contribution of ETA and ETB in the proliferative effect of ET-1.
  • The ETB agonist, sarafotoxin S6c, stimulates PLC activity 60% less than ET-1 but is as potent as ET-1 to increase ERK1/2 phosphorylation and induce proliferation.
  • Although ETA and ETB antagonists partially reduce ET-1 stimulated PLC activity, they are without effect on ET-1-induced ERK1/2 phosphorylation and proliferation.
  • Only the simultaneous use of ETA and ETB antagonists reduces ET-1-triggered ERK1/2 activation.
  • Finally, treatment of ELT3 cells with ETB but not ETA-directed small interfering RNA reduces the proliferative effect of ET-1.
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA / biosynthesis. Endothelin-1 / metabolism. Endothelin-3 / metabolism. Enzyme Activation. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Iodine Radioisotopes / metabolism. Rats. Rats, Long-Evans. Type C Phospholipases / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Peptides. 2000 Apr;21(4):543-51 [10822110.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30958-67 [12045200.001]
  • [Cites] Biol Reprod. 2001 Aug;65(2):496-506 [11466218.001]
  • [Cites] Recent Prog Horm Res. 2002;57:277-94 [12017548.001]
  • [Cites] Pharmacol Rev. 2002 Jun;54(2):219-26 [12037137.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C251-60 [12055094.001]
  • [Cites] Cell Mol Neurobiol. 2002 Apr;22(2):207-26 [12363203.001]
  • [Cites] J Soc Gynecol Investig. 2003 Jan;10(1):11-20 [12517588.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] Can J Physiol Pharmacol. 2003 Feb;81(2):95-104 [12710521.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Aug;285(2):C409-18 [12700139.001]
  • [Cites] Int J Dev Biol. 2003 Jun;47(5):315-25 [12895026.001]
  • [Cites] Mol Hum Reprod. 2003 Sep;9(9):541-9 [12900513.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1436-43 [14973117.001]
  • [Cites] Hum Reprod Update. 2004 May-Jun;10(3):207-20 [15140868.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27679-87 [15075338.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Mar 15;175(2):556-61 [1850245.001]
  • [Cites] Mol Pharmacol. 1993 Feb;43(2):127-31 [8429819.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892-6 [8197152.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):485-94 [7935329.001]
  • [Cites] Mol Cell Endocrinol. 1994 Jul;103(1-2):165-70 [7958393.001]
  • [Cites] Biochim Biophys Acta. 1994 Nov 10;1224(2):288-94 [7981244.001]
  • [Cites] Pharmacol Rev. 1994 Sep;46(3):325-415 [7831383.001]
  • [Cites] J Endocrinol. 1995 Jan;144(1):127-34 [7891013.001]
  • [Cites] Am J Physiol. 1995 May;268(5 Pt 1):E825-31 [7762634.001]
  • [Cites] Am J Pathol. 1995 Jun;146(6):1568-79 [7539981.001]
  • [Cites] N Engl J Med. 1995 Aug 10;333(6):356-63 [7609754.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):209-14 [7626456.001]
  • [Cites] Eur J Pharmacol. 1995 Oct 4;285(1):89-94 [8846815.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S380-4 [8587421.001]
  • [Cites] Brain Res. 1998 Mar 2;785(2):253-61 [9518640.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):C379-85 [9950765.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Jun;289(3):1385-90 [10336530.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500 [10500205.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 1):C614-5 [10516090.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 1):C616-27 [10516091.001]
  • [Cites] Bull Cancer. 1999 Sep;86(9):773-8 [10519970.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8945-53 [15604257.001]
  • [Cites] Biol Reprod. 2005 Jan;72(1):69-77 [15355882.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):179-88 [15467714.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):77-88 [15950764.001]
  • [Cites] Fertil Steril. 2005 Aug;84(2):474-84 [16084893.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6296s-6300s [17062717.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):5873-82 [16959847.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1725-34 [17308114.001]
  • [Cites] Curr Vasc Pharmacol. 2007 Jul;5(3):239-48 [17627567.001]
  • [Cites] ScientificWorldJournal. 2007;7:58-63 [17982577.001]
  • [Cites] Hum Reprod. 2008 Feb;23(2):440-6 [17993476.001]
  • [Cites] Br J Pharmacol. 2008 May;154(1):13-24 [18362896.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(8):1443-51 [18325824.001]
  • [Cites] Biophys J. 2008 Jul;95(1):483-92 [18424490.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):657-68 [18722871.001]
  • [Cites] Can J Physiol Pharmacol. 2008 Aug;86(8):526-35 [18758500.001]
  • [Cites] Endocrinology. 2009 May;150(5):2436-45 [19179429.001]
  • [Cites] Fertil Steril. 2002 Jul;78(1):1-12 [12095482.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3766-72 [12097287.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S386-9 [11078428.001]
  • (PMID = 19628575.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelin-3; 0 / Iodine Radioisotopes; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; 9007-49-2 / DNA; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.4.- / Type C Phospholipases
  • [Other-IDs] NLM/ PMC2754684
  •  go-up   go-down


55. Murugesan M, Courtauld E, Fisher C, Nathan S: Renal capsular PEComa--a rare cause of surgically correctable renal hypertension. Int Urol Nephrol; 2007;39(3):705-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mass had a smooth outer surface and the cut surface showed firm whitish tissue with a few small cysts.
  • Perivascular Epitheloid Cell tumor (PEComa), a recently defined tumor, is extremely rare.
  • PEComa's are usually benign, but cases have been reported in the literature which has an unfavourable outcome with metastatic dissemination.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2006 Jan;48(1):75-82 [16359539.001]
  • [Cites] Pathology. 1991 Jul;23(3):185-8 [1664078.001]
  • [Cites] Eur J Cancer. 1993;29A(13):1903-7 [8260252.001]
  • (PMID = 17318350.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K, Remaley AT: High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res; 2010 Sep;8(9):1284-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Knockdown of ABCA1 but not ABCG1 or SR-BI by small interfering RNA (siRNA) inhibited HDL-induced cell proliferation, migration, and ERK1/2 and Akt signal transduction in PC-3 cells.
  • Moreover, after treatment of LNCaP cells with charcoal-stripped fetal bovine serum, ABCA1 was induced ∼10-fold, enabling HDL to induce ERK1/2 activation, whereas small interfering RNA knockdown of ABCA1 inhibited HDL-induced ERK1/2 activation.
  • In human prostate biopsy samples, ABCA1 mRNA expression was ∼2-fold higher in the androgen deprivation therapy group than in subjects with benign prostatic hyperplasia or pretreatment prostate cancer groups.
  • [MeSH-minor] ATP Binding Cassette Transporter 1. Androgens / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cholesterol / metabolism. Enzyme Activation / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Intracellular Space / drug effects. Intracellular Space / metabolism. Male. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / metabolism. Simvastatin / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 AACR.
  • [Cites] Curr Opin Lipidol. 2004 Dec;15(6):659-65 [15529025.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7682-5 [15520169.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):883-91 [15705602.001]
  • [Cites] Am J Epidemiol. 2005 Aug 15;162(4):318-25 [16014776.001]
  • [Cites] Trends Cardiovasc Med. 2005 Oct;15(7):265-71 [16226682.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 26;344(1):226-32 [16600185.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):463-71 [17252538.001]
  • [Cites] Prostate. 2007 Jul 1;67(10):1061-9 [17469127.001]
  • [Cites] Clin Chim Acta. 2007 Aug;383(1-2):78-84 [17512923.001]
  • [Cites] Atherosclerosis. 2008 Jan;196(1):180-9 [17466310.001]
  • [Cites] J Am Coll Cardiol. 2008 Apr 22;51(16):1604-12 [18420105.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1203-15 [18939908.001]
  • [Cites] J Urol. 2009 May;181(5):1998-2006; discussion 2007-8 [19286225.001]
  • [Cites] Endocr J. 2009;56(3):317-34 [18753704.001]
  • [Cites] Prostate. 2009 Oct 1;69(14):1493-506 [19536794.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):60-7 [10585584.001]
  • [Cites] J Urol. 2000 Mar;163(3):1027-32 [10688043.001]
  • [Cites] Carcinogenesis. 2001 May;22(5):701-7 [11323387.001]
  • [Cites] J Lipid Res. 2001 Jun;42(6):967-75 [11369805.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31780-5 [11427538.001]
  • [Cites] Circulation. 2001 Oct 16;104(16):1978-83 [11602504.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):846-52 [12115487.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5962-74 [12138205.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7 [12207878.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9142-9 [12511559.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):712-9 [12615688.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):802-8 [12637339.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):54-69 [14689582.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1515-21 [14973113.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):790-4 [15033469.001]
  • [Cites] Cancer. 1973 Jul;32(1):196-205 [4123791.001]
  • [Cites] Anal Biochem. 1975 May 12;65(1-2):42-9 [165752.001]
  • [Cites] Methods Enzymol. 1986;129:628-44 [3523160.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):598-604 [2743254.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9 [8105097.001]
  • [Cites] Science. 1996 Jan 26;271(5248):518-20 [8560269.001]
  • [Cites] J Urol. 2005 Feb;173(2):342-59 [15643172.001]
  • (PMID = 20671065.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / NIH0013975756; United States / PHS HHS / / NIH0013975756; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA1 protein, human; 0 / ATP Binding Cassette Transporter 1; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Lipoproteins, HDL; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 97C5T2UQ7J / Cholesterol; AGG2FN16EV / Simvastatin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS222887; NLM/ PMC2941551
  •  go-up   go-down


57. Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T: Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer; 2010 Sep 1;127(6):1332-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we examined the immunohistochemical expression of HDAC1, HDAC2 and HDAC3 using tissues obtained from 115 cases of ovarian tumors and compared it with that of Ki-67 (a growth marker), p21, and E-cadherin and clinicopathological parameters.
  • In addition, we analyzed the effect of specific siRNA for HDAC1, HDAC2 and HDAC3 on the expression of cell cycle-related molecules and E-cadherin to clarify the functional difference among the 3 HDACs.
  • The results indicated that the immunohistochemical expression of nuclear HDAC1, HDAC2 and HDAC3 proteins increased stepwise in benign, borderline and malignant tumors.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. RNA Interference. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049841.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Small Interfering; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3
  •  go-up   go-down


58. Safioleas MC, Constantinos K, Michael S, Konstantinos G, Constantinos S, Alkiviadis K: Benign multicystic peritoneal mesothelioma: a case report and review of the literature. World J Gastroenterol; 2006 Sep 21;12(35):5739-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: a case report and review of the literature.
  • Benign multicystic peritoneal mesothelioma (BMPM) is a rare tumor that occurs mainly in women in their reproductive age.
  • The pathogenesis of BMPM is unclear and a controversy regarding its neoplastic and reactive nature exists.
  • Upright plain abdominal film revealed small bowel loops with air-fluid levels.
  • She was diagnosed having an incarcerated incisional hernia that resulted in intestinal obstruction.
  • The patient underwent surgery during which a cystic mass of the right ovary measuring 6 cm multiply 5 cm multiply 4 cm, four small cysts of the small bowel (1 cm in diameter) and a cyst at the retroperitoneum measuring 11 cm multiply 10 cm multiply 3 cm were found.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Mesothelioma, Cystic / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasms / diagnosis. Neoplasms / etiology. Neoplasms / pathology. Neoplasms / surgery


59. Draper H, Chitayat D, Ein SH, Langer JC: Long-term functional results following resection of neonatal sacrococcygeal teratoma. Pediatr Surg Int; 2009 Mar;25(3):243-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Sacrococcygeal teratoma (SCT) is the most common congenital neoplasm in neonates.
  • Of the 42 remaining cases, 39 were benign and 3 were malignant; 2 of the former developed malignant recurrences.
  • Median age of respondents was 16.7 years (3-29), and none of the respondents had a recurrent tumor.
  • CONCLUSIONS: Functional results after resection of neonatal SCT are excellent, with only a small number of patients reporting problems with fecal or urinary continence, or lower extremity weakness.

  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1990 Jun;25(6):679-80 [2359006.001]
  • [Cites] Eur J Pediatr Surg. 2001 Oct;11(5):305-10 [11719867.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):274-7 [3559872.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):398-410 [6684416.001]
  • [Cites] J Urol. 1993 Sep;150(3):948-9 [8345616.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1165-7 [8308684.001]
  • [Cites] Pediatr Radiol. 1992;22(7):509-11 [1491908.001]
  • [Cites] J Pediatr Surg. 1998 Jun;33(6):899-903 [9660225.001]
  • [Cites] J Pediatr Surg. 2007 Jun;42(6):1122-6 [17560233.001]
  • [Cites] J Pediatr Surg. 1992 Nov;27(11):1447-50 [1282543.001]
  • [Cites] Am Fam Physician. 1996 Aug;54(2):611-8, 627 [8701840.001]
  • [Cites] Ultrasound Obstet Gynecol. 1997 Jun;9(6):425-8 [9239831.001]
  • [Cites] Med Pediatr Oncol. 1984;12 (4):231-2 [6205243.001]
  • [Cites] Z Kinderchir. 1987 Dec;42(6):358-61 [3439358.001]
  • [Cites] Eur J Pediatr Surg. 1994 Apr;4(2):125-7 [8025097.001]
  • [Cites] Pediatr Surg Int. 1999;15(8):573-6 [10631738.001]
  • [Cites] Am J Obstet Gynecol. 1989 May;160(5 Pt 1):1145-50 [2658603.001]
  • [Cites] J Urol. 1994 Jan;151(1):174-6 [8254808.001]
  • [Cites] Ann Surg. 1980 Mar;191(3):382-4 [7362303.001]
  • (PMID = 19189110.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Rashmi MS, Alka KD, Seema C: Oral hobnail hemangioma--a case report. Quintessence Int; 2008 Jun;39(6):507-10